[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 105
1. Quesenberry PJ, Aliotta JM: Cellular phenotype switching and microvesicles. Adv Drug Deliv Rev; 2010 Sep 30;62(12):1141-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The capacity of marrow to convert to non-hematopoietic cells related to vesicle cross-communication may underlie the phenomena of stem cell plasticity.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • [Cites] Development. 2001 Dec;128(24):5181-8 [11748153.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):460-6 [11981558.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Hypertension. 2003 Feb;41(2):211-7 [12574084.001]
  • [Cites] Exp Cell Res. 2003 May 1;285(2):243-57 [12706119.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8407-11 [12815096.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8048-52 [12821779.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Aug 1;168(3):318-22 [12724127.001]
  • [Cites] Cytotherapy. 2003;5(6):523-33 [14660048.001]
  • [Cites] FEBS Lett. 2004 Jan 2;556(1-3):249-52 [14706858.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):243-52 [14722616.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):47-51 [14757412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1297-302 [14745008.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1910-5 [15072974.001]
  • [Cites] FASEB J. 2004 Jun;18(9):977-9 [15059973.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9683-8 [15210972.001]
  • [Cites] Curr Opin Hematol. 2004 May;11(3):156-64 [15257014.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7045-9 [15466198.001]
  • [Cites] Br J Haematol. 1967 May;13(3):269-88 [6025241.001]
  • [Cites] Anal Biochem. 1979 Sep 15;98(1):53-9 [396817.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):4064-9 [7008934.001]
  • [Cites] J Cell Biol. 1985 Sep;101(3):942-8 [2993317.001]
  • [Cites] Cell. 1987 Dec 24;51(6):987-1000 [3690668.001]
  • [Cites] Trends Genet. 1989 Aug;5(8):268-72 [2686116.001]
  • [Cites] EMBO J. 1992 Dec;11(12):4557-64 [1385117.001]
  • [Cites] Genes Dev. 1995 May 15;9(10):1250-62 [7758949.001]
  • [Cites] Circulation. 1996 Jan 15;93(2):229-37 [8548893.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):1161-72 [8642258.001]
  • [Cites] Nature. 1997 Feb 27;385(6619):810-3 [9039911.001]
  • [Cites] Mol Biol Cell. 1997 Dec;8(12):2631-45 [9398681.001]
  • [Cites] Stroke. 1998 Sep;29(9):1770-7 [9731593.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3257-66 [15284116.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Dec 1;170(11):1158-63 [15282197.001]
  • [Cites] Proteomics. 2005 May;5(7):1940-52 [15825151.001]
  • [Cites] J Cell Sci. 2005 Jun 1;118(Pt 11):2441-50 [15923657.001]
  • [Cites] Cardiovasc Res. 2005 Jul 1;67(1):30-8 [15878159.001]
  • [Cites] J Cell Sci. 2005 Jul 1;118(Pt 13):2849-58 [15976444.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1333-8 [12423687.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Dec;27(6):645-51 [12444022.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):33-42 [12478067.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):680-6 [16027045.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1516-21 [16212402.001]
  • [Cites] J Am Soc Nephrol. 2005 Nov;16(11):3381-8 [16192427.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4443-55 [16220532.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Jan 15;173(2):171-9 [16179642.001]
  • [Cites] Proteomics. 2006 Jan;6(1):153-71 [16342139.001]
  • [Cites] Exp Hematol. 2006 Feb;34(2):230-41 [16459191.001]
  • [Cites] Diabetes Metab. 2006 Feb;32(1):82-5 [16523191.001]
  • [Cites] Eur Heart J. 2006 Apr;27(7):817-23 [16434416.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jul;55(7):808-18 [16283305.001]
  • [Cites] Leukemia. 2006 May;20(5):847-56 [16453000.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4795-801 [16651434.001]
  • [Cites] Biol Cell. 2006 Aug;98(8):491-501 [16677129.001]
  • [Cites] Stem Cells. 2006 Aug;24(8):1986-92 [16868209.001]
  • [Cites] Stem Cells. 2006 Sep;24(9):2071-7 [16709877.001]
  • [Cites] Stem Cells. 2006 Oct;24(10):2299-308 [16794262.001]
  • [Cites] Genes Dev. 2006 Nov 1;20(21):3010-21 [17079688.001]
  • [Cites] Immunol Lett. 2006 Nov 15;107(2):102-8 [17067686.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2127-36 [17148675.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1120-8 [16980338.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):369-78 [17377526.001]
  • [Cites] Nat Cell Biol. 2007 Jun;9(6):654-9 [17486113.001]
  • [Cites] Mol Cell Proteomics. 2007 Jun;6(6):1088-102 [17339633.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2440-8 [17536014.001]
  • [Cites] Proteomics. 2007 Oct;7(20):3681-92 [17879999.001]
  • [Cites] Nature. 2007 Nov 15;450(7168):435-9 [17960135.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4646-55 [17956143.001]
  • [Cites] Diabetes Metab. 2008 Feb;34 Suppl 1:S27-32 [18358424.001]
  • [Cites] Stem Cells Dev. 2008 Apr;17(2):207-19 [18447637.001]
  • [Cites] Nature. 2008 May 8;453(7192):236-40 [18368049.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Jun 1;177(11):1268-75 [18310479.001]
  • [Cites] Gynecol Oncol. 2008 Jul;110(1):13-21 [18589210.001]
  • [Cites] Cell Death Differ. 2009 Jan;16(1):70-8 [19008921.001]
  • [Cites] Science. 2008 Dec 19;322(5909):1811-5 [19095934.001]
  • [Cites] Inflamm Res. 2009 Jan;58(1):1-8 [19132498.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):896-900 [19212410.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1977-81 [19064723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3794-9 [19234131.001]
  • [Cites] Nature. 2009 Jul 2;460(7251):60-5 [19571878.001]
  • [Cites] Blood. 2009 Jul 16;114(3):723-32 [19369228.001]
  • [Cites] Nat Rev Immunol. 2009 Aug;9(8):581-93 [19498381.001]
  • [Cites] BMC Cancer. 2009;9:244 [19619303.001]
  • [Cites] Sci Signal. 2009 Dec 8;2(100):ra81 [19996457.001]
  • [Cites] Exp Hematol. 2010 Mar;38(3):233-45 [20079801.001]
  • [Cites] Thromb Res. 2010 Apr;125(4):332-9 [20117824.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jun;59(6):841-50 [20043223.001]
  • [Cites] Ann Oncol. 2010 Sep;21(9):1851-7 [20147742.001]
  • [Cites] Science. 2005 May 20;308(5725):1121-2 [15905387.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3791-9 [10572093.001]
  • [Cites] Blood. 2000 Feb 1;95(3):930-5 [10648405.001]
  • [Cites] Circulation. 2000 Feb 29;101(8):841-3 [10694520.001]
  • [Cites] Cytometry. 2000 Jul 1;40(3):173-81 [10878559.001]
  • [Cites] Curr Biol. 2000 Aug 24;10(16):1005-8 [10985390.001]
  • [Cites] Placenta. 2000 Sep;21(7):597-602 [10985960.001]
  • [Cites] Cell. 2001 May 4;105(3):369-77 [11348593.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12):7309-18 [11390481.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3143-9 [11698303.001]
  • [Cites] Immunity. 2001 Nov;15(5):825-35 [11728343.001]
  • (PMID = 20558219.001).
  • [ISSN] 1872-8294
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 1P20 RR025179-01; United States / NHLBI NIH HHS / HL / K08 HL086868; United States / NHLBI NIH HHS / HL / 5K08HL086868-03VV; United States / NHLBI NIH HHS / HL / R01 HL103726; United States / NCRR NIH HHS / RR / P20 RR025179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS216266; NLM/ PMC2955803
  •  go-up   go-down


2. Seaberg EC, Wiley D, Martínez-Maza O, Chmiel JS, Kingsley L, Tang Y, Margolick JB, Jacobson LP, Multicenter AIDS Cohort Study (MACS): Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer; 2010 Dec 1;116(23):5507-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007.
  • BACKGROUND: The incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) among human immunodeficiency virus (HIV)-infected individuals declined after the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, but the cancer risk associated with HIV infection during the HAART era remains to be clarified.
  • METHODS: Cancer incidence among HIV-infected and HIV-uninfected participants in the Multicenter AIDS (acquired immunodeficiency syndrome) Cohort Study (MACS) between 1984 and 2007 was compared with the expected incidence using US population-based data from the Surveillance, Epidemiology, and End Results (SEER) program.
  • Age- and race-adjusted cancer incidence rates were also compared HIV by status and over time within the MACS.
  • Compared with SEER, MACS HIV-infected men had significantly (P<.05) elevated rates of KS (standardized incidence ratio [SIR], 139.10), NHL (SIR, 36.80), Hodgkin lymphoma (HL)(SIR, 7.30), and anal cancer (SIR, 25.71).
  • Within MACS, HIV infection was found to be independently associated with each of these cancers across the entire follow-up period, and KS (incidence rate ratio [IRR], 54.93), NHL (IRR, 11.18), and anal cancer (IRR, 18.50) were each found to be significantly elevated among HIV-infected men during the HAART era.
  • Among these men, the incidence of KS and NHL declined (IRR, 0.13 and 0.23, respectively), the incidence of anal cancer increased (IRR, 5.84), and the incidence of HL remained statistically unchanged (IRR, 0.75) from the pre-HAART to the HAART era.
  • CONCLUSIONS: Cancer risk remains elevated among HIV-infected men who have sex with men, highlighting the continuing need for appropriate cancer screening in this population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Ann Epidemiol. 2008 Mar;18(3):230-4 [18083545.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):1-2 [19339933.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):56-63 [15654781.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] AIDS. 2005 Nov 18;19(17):2009-18 [16260908.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):901-12 [10951356.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Clin Epidemiol. 2001 Dec;54 Suppl 1:S29-34 [11750207.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Am J Public Health. 2006 Jun;96(6):1020-7 [16670218.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1725-30 [9848347.001]
  • [CommentIn] Cancer. 2010 Dec 1;116(23):5344-7 [20960526.001]
  • (PMID = 20672354.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / U01-AI-35042; United States / NCRR NIH HHS / RR / M01 RR000052-46; United States / NIAID NIH HHS / AI / U01 AI035041-17; United States / NCRR NIH HHS / RR / 5-M01-RR-00052; United States / NIAID NIH HHS / AI / U01 AI035039-17; United States / NIAID NIH HHS / AI / AI035039-17; United States / NIAID NIH HHS / AI / U01 AI035042-17; United States / NIAID NIH HHS / AI / U01-AI-35041; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / AI035042-17; United States / NIAID NIH HHS / AI / AI035043-17; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / AI035040-17; United States / NIAID NIH HHS / AI / U01 AI035043-17; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NIAID NIH HHS / AI / U01-AI-35040; United States / NIAID NIH HHS / AI / U01 AI035040-17; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218249; NLM/ PMC2991510
  • [Investigator] Margolick JB; Jacobson LP; Phair JP; Wolinsky SM; Detels R; Rinaldo CR
  •  go-up   go-down


3. Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM: Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med; 2009;7:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009.
  • The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy.
  • The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting.
  • The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy;.
  • Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet.
  • It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms.
  • [MeSH-minor] Humans. Japan. National Cancer Institute (U.S.). Reproducibility of Results. United States. United States Food and Drug Administration


Advertisement
4. Lopes de Campos WR, Coopusamy D, Morris L, Mayosi BM, Khati M: Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrob Agents Chemother; 2009 Jul;53(7):3056-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The long-term cumulative cytotoxicity of antiretrovirals (ARVs) is among the major causes of treatment failure in patients infected with human immunodeficiency virus (HIV) and patients with AIDS.
  • These data support the development of B40 and related EI aptamers as new ARVs with no cytotoxicity at the estimated potential therapeutic dose.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Drug Metab. 2007 Jun;8(5):407-47 [17584015.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2007 Oct;34(10):1051-7 [17714093.001]
  • [Cites] J Antimicrob Chemother. 2007 Dec;60(6):1195-205 [17890281.001]
  • [Cites] J Cardiometab Syndr. 2008 Spring;3(2):106-10 [18453811.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 2008 Sep;151(1):10-27 [18602321.001]
  • [Cites] Virology. 2008 Nov 10;381(1):46-54 [18799178.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9 [14506019.001]
  • [Cites] Nat Rev Drug Discov. 2003 Oct;2(10):812-22 [14526384.001]
  • [Cites] J Virol. 2003 Dec;77(23):12692-8 [14610191.001]
  • [Cites] Am J Ther. 2004 Jul-Aug;11(4):262-77 [15266218.001]
  • [Cites] Curr Med Chem. 2004 Aug;11(15):1983-93 [15279562.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7426-31 [15492266.001]
  • [Cites] Eur J Pharmacol. 1975 Nov;34(1):181-7 [1241962.001]
  • [Cites] Psychopharmacology (Berl). 1978 Apr 14;57(1):33-8 [96466.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100 [2413459.001]
  • [Cites] J Histochem Cytochem. 1987 Jan;35(1):23-32 [3025289.001]
  • [Cites] Biochem Pharmacol. 1988 Oct 1;37(19):3543-8 [3178868.001]
  • [Cites] Biochem Pharmacol. 1989 Mar 15;38(6):901-5 [2495009.001]
  • [Cites] Science. 1990 Apr 20;248(4953):358-61 [2183354.001]
  • [Cites] J Neurochem. 1990 Oct;55(4):1166-9 [2398352.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1411-3 [1701568.001]
  • [Cites] J Neural Transm Suppl. 1990;32:41-7 [2089104.001]
  • [Cites] Ann Intern Med. 1992 Feb 15;116(4):311-3 [1733387.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Apr;36(4):733-9 [1380229.001]
  • [Cites] Circ Res. 1994 Feb;74(2):344-8 [8293572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4096-100 [8171040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4 [7937889.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2484-8 [7708670.001]
  • [Cites] Nat Med. 1995 May;1(5):417-22 [7585087.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5 [8592986.001]
  • [Cites] Antimicrob Agents Chemother. 1996 Feb;40(2):292-7 [8834868.001]
  • [Cites] Life Sci. 1996;59(16):1341-9 [8876663.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Jun;41(6):1250-5 [9174179.001]
  • [Cites] Oncogene. 1998 Jan 22;16(3):369-80 [9467962.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Mar;42(3):612-7 [9517941.001]
  • [Cites] AIDS. 1998 May 7;12(7):F51-8 [9619798.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1881-3 [9652687.001]
  • [Cites] AIDS. 1999 Nov 12;13(16):2311-2 [10563722.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):147-51 [10653595.001]
  • [Cites] AIDS. 2000 Feb 18;14(3):F25-32 [10716495.001]
  • [Cites] Clin Ther. 2000 Jun;22(6):685-708 [10929917.001]
  • [Cites] Lancet. 2000 Oct 21;356(9239):1423-30 [11052597.001]
  • [Cites] J Anal Toxicol. 2001 Mar;25(2):147-51 [11300508.001]
  • [Cites] Pharm Res. 2000 Dec;17(12):1503-10 [11303960.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7320-6 [11058599.001]
  • [Cites] Chem Res Toxicol. 2001 Jun;14(6):611-50 [11409933.001]
  • [Cites] J HIV Ther. 2001 Mar;6(1):13-6 [11501196.001]
  • [Cites] AIDS. 2001 Jul 27;15(11):1450-2 [11504973.001]
  • [Cites] Chem Res Toxicol. 2001 Sep;14(9):1139-62 [11559028.001]
  • [Cites] HIV Med. 2001 Jul;2(3):163-5 [11737396.001]
  • [Cites] Retina. 2002 Apr;22(2):143-52 [11927845.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6901-8 [12460905.001]
  • [Cites] Ophthalmology. 2003 May;110(5):979-86 [12750101.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2656-68 [12826641.001]
  • [Cites] J Virol. 1998 Sep;72(9):7532-41 [9696850.001]
  • [Cites] AIDS. 1998 Nov 12;12(16):2161-7 [9833857.001]
  • [Cites] Lancet. 1999 Sep 25;354(9184):1112-5 [10509516.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2805-16 [15625332.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Feb;312(2):583-91 [15523003.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21 [15917527.001]
  • [Cites] RNA. 2005 Jun;11(6):873-84 [15923374.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:924-31 [15761470.001]
  • [Cites] Int J Antimicrob Agents. 2005 Jul;26(1):88-91 [15878262.001]
  • [Cites] J Virol. 2005 Nov;79(21):13806-10 [16227301.001]
  • [Cites] Curr Pharm Des. 2005;11(29):3847-52 [16305515.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Nov;82(3):488-94 [16298423.001]
  • [Cites] Clin Ther. 2006 Jan;28(1):36-44 [16490578.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1497-502 [16847404.001]
  • [Cites] Pharmacol Ther. 2006 Nov;112(2):564-87 [16824612.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):166-72 [16758472.001]
  • (PMID = 19364860.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Aptamers, Nucleotide; 0 / DNA, Mitochondrial; 0 / DNA, Viral; 0 / HIV Envelope Protein gp120; 0 / HIV Integrase Inhibitors; 0 / HIV Protease Inhibitors; 0 / Reverse Transcriptase Inhibitors; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; EC 1.4.3.4 / Monoamine Oxidase; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  • [Other-IDs] NLM/ PMC2704642
  •  go-up   go-down


5. Wang X, Tanaka H, Baba M, Cheng YC: Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells. Antimicrob Agents Chemother; 2009 Aug;53(8):3317-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mechanism-of-action study showed that the efflux of 4'-Ed4T or AZT nucleoside might be due to unknown nucleoside transporters which were not related to the equilibrative nucleoside transporters, while the efflux of AZT monophosphate might be due to multidrug resistance protein 4 (MRP4/ABCC4).

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. STAVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Ther. 2000 Jun;22(6):685-708 [10929917.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):422-7 [16280696.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1624-31 [11912132.001]
  • [Cites] Acta Biochim Pol. 2005;52(4):749-58 [16265592.001]
  • [Cites] Antiviral Res. 2007 Mar;73(3):185-91 [17109975.001]
  • [Cites] Antimicrob Agents Chemother. 2007 May;51(5):1687-93 [17353236.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Aug;51(8):2701-8 [17548498.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Nov;51(11):3870-9 [17724147.001]
  • [Cites] Leuk Res. 2008 May;32(5):799-809 [17996297.001]
  • [Cites] Mol Pharmacol. 2003 Jan;63(1):65-72 [12488537.001]
  • [Cites] Nat Med. 2003 Jul;9(7):867-73 [12835707.001]
  • [Cites] Bioorg Med Chem Lett. 2003 Nov 3;13(21):3775-7 [14552777.001]
  • [Cites] Antimicrob Agents Chemother. 2004 May;48(5):1640-6 [15105115.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1529-37 [15238771.001]
  • [Cites] JAMA. 2004 Jul 14;292(2):251-65 [15249575.001]
  • [Cites] Biochem Pharmacol. 2004 Oct 1;68(7):1363-70 [15345326.001]
  • [Cites] Anal Biochem. 1974 Aug;60(2):545-50 [4367536.001]
  • [Cites] Biochem J. 1981 Nov 15;200(2):295-305 [6280683.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Mar;42(3):612-7 [9517941.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Apr;42(4):833-9 [9559792.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Jul;42(7):1799-804 [9661024.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1048-51 [10470083.001]
  • [Cites] Virus Res. 2005 Feb;107(2):151-64 [15649561.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Aug;49(8):3355-60 [16048947.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40847-57 [11526116.001]
  • (PMID = 19470503.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI038204; United States / NIAID NIH HHS / AI / R56 AI038204; United States / NIAID NIH HHS / AI / AI-38204
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4'-ethynylstavudine; 0 / ABCC4 protein, human; 0 / Anti-HIV Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / Phosphodiesterase Inhibitors; 4B9XT59T7S / Zidovudine; 64ALC7F90C / Dipyridamole; BO9LE4QFZF / Stavudine; VC2W18DGKR / Thymidine
  • [Other-IDs] NLM/ PMC2715651
  •  go-up   go-down


6. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis; 2006 Feb;19(1):14-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
  • PURPOSE OF REVIEW: Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer.
  • In addition a number of other cancers occur at increased frequency in this population group but are not AIDS-defining illnesses.
  • This review discusses the impact of highly active antiretroviral therapy on the epidemiology and outcome of AIDS-defining cancers.
  • In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths.
  • As people with HIV live longer with highly active antiretroviral therapy, an increased incidence of other non AIDS-defining cancers that have no known association with oncogenic infections is becoming apparent.
  • SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers - particularly Kaposi's sarcoma and non-Hodgkin's lymphoma - may be balanced by the increasing numbers of non AIDS-defining cancers.
  • [MeSH-minor] Female. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology


7. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI: HIV infection and the risk of cancers with and without a known infectious cause. AIDS; 2009 Nov 13;23(17):2337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Adult HIV-infected and matched HIV-uninfected members of Kaiser Permanente followed between 1996 and 2007 for incident AIDS-defining cancers (ADCs), infection-related non-AIDS-defining cancers (NADCs; anal squamous cell, vagina/vulva, Hodgkin's lymphoma, penis, liver, human papillomavirus-related oral cavity/pharynx, stomach) and infection-unrelated NADC (all other NADCs).
  • HIV-infected persons experienced 552 ADC, 221 infection-related NADC, and 388 infection-unrelated NADC.
  • HIV-uninfected persons experienced 179 ADC, 284 infection-related NADC, and 3418 infection-unrelated NADC.
  • The rate ratio for infection-related NADC was 9.2 (95% CI: 7.7-11.1), also with decreases in the rate ratio over time (P < 0.001).
  • These results were largely influenced by anal squamous cell cancer and Hodgkin's lymphoma.
  • Among infection-unrelated NADCs, other anal, skin, other head and neck, and lung cancer rates were higher and prostate cancer rates lower in HIV-infected persons.
  • Among all infection-unrelated NADCs, the rate ratio decreased over time only for lung cancer (P = 0.007).


8. van der Weijden T, Légaré F, Boivin A, Burgers JS, van Veenendaal H, Stiggelbout AM, Faber M, Elwyn G: How to integrate individual patient values and preferences in clinical practice guidelines? A research protocol. Implement Sci; 2010;5:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A purposive sample of 20 to 25 key-informants will be selected among three groups of stakeholders: health professionals using guidelines (e.g., physicians, nurses); experts at the macro- and meso-level, including guideline and decision aids developers, policy makers, and researchers; and patient representatives.
  • This study is not about patient participation in guideline development, a closely related and important issue that does not however substitute for, or guarantee individual patient involvement in clinical decisions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2009 Feb 28;373(9665):774-9 [18835641.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):875-82 [18781148.001]
  • [Cites] BMJ. 2008;337:a1864 [18977792.001]
  • [Cites] Implement Sci. 2008;3:57 [19117509.001]
  • [Cites] JAMA. 2009 Feb 25;301(8):868-9 [19244197.001]
  • [Cites] PLoS One. 2009;4(3):e4705 [19259269.001]
  • [Cites] Med Care. 2009 Aug;47(8):908-15 [19543120.001]
  • [Cites] JAMA. 1991 Jan 2;265(1):105-8 [1984107.001]
  • [Cites] BMJ. 1996 Jan 13;312(7023):71-2 [8555924.001]
  • [Cites] J Eval Clin Pract. 1998 Feb;4(1):1-9 [9524908.001]
  • [Cites] Spine (Phila Pa 1976). 1998 May 1;23(9):1073-9 [9589550.001]
  • [Cites] BMJ. 1998 Sep 26;317(7162):858-61 [9748183.001]
  • [Cites] J Health Serv Res Policy. 1997 Apr;2(2):112-21 [10180362.001]
  • [Cites] Soc Sci Med. 1999 Sep;49(5):651-61 [10452420.001]
  • [Cites] JAMA. 1999 Oct 20;282(15):1458-65 [10535437.001]
  • [Cites] BMJ. 2000 May 20;320(7246):1380-4 [10818030.001]
  • [Cites] Br J Gen Pract. 2000 Nov;50(460):892-9 [11141876.001]
  • [Cites] Lancet. 2001 Aug 18;358(9281):571-4 [11520546.001]
  • [Cites] BMJ. 2001 Nov 24;323(7323):1218-22 [11719412.001]
  • [Cites] Health Expect. 2002 Jun;5(2):95-103 [12031050.001]
  • [Cites] Health Expect. 2002 Sep;5(3):185-6 [12199657.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):716-24 [16091574.001]
  • [Cites] BMJ. 2006 Aug 26;333(7565):417 [16908462.001]
  • [Cites] Health Expect. 2006 Dec;9(4):333-42 [17083560.001]
  • [Cites] Health Res Policy Syst. 2006;4:22 [17147811.001]
  • [Cites] J Rheumatol. 2007 May;34(5):1174-7 [17477482.001]
  • [Cites] Z Arztl Fortbild Qualitatssich. 2007;101(4):241-6 [17601179.001]
  • [Cites] Ann Rheum Dis. 2007 Dec;66(12):1560-7 [17660219.001]
  • [Cites] Can Fam Physician. 2007 Aug;53(8):1326-7 [17872848.001]
  • [Cites] Psychother Psychosom. 2008;77(4):219-26 [18418028.001]
  • [Cites] BMJ. 2008 Apr 26;336(7650):924-6 [18436948.001]
  • [Cites] BMJ. 2008 May 10;336(7652):1049-51 [18467413.001]
  • [Cites] JAMA. 2008 Jul 23;300(4):436-8 [18647988.001]
  • [Cites] Patient Educ Couns. 2008 Dec;73(3):413-7 [18768285.001]
  • [Cites] BMC Health Serv Res. 2008;8:221 [18954427.001]
  • (PMID = 20205815.001).
  • [ISSN] 1748-5908
  • [Journal-full-title] Implementation science : IS
  • [ISO-abbreviation] Implement Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2824684
  •  go-up   go-down


9. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX: Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine; 2008 Aug 19;26 Suppl 10:K17-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In men, 80-85% of anal cancers and close to 50% of penile cancers are associated with HPV infection.
  • In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers.
  • There is limited data available on the natural history and HPV-related diseases in the genital tract in men, although studies are ongoing.
  • Among HPV DNA positive ano-genital cancer cases, HPV-16 is the most frequently found followed distantly by HPV-18.
  • In benign HPV-related diseases such as genital warts or recurrent respiratory papillomatosis HPV-6 and 11, the two most frequent non-oncogenic types, are the predominant types detected.
  • In this article we summarize and review studies describing the natural history of HPV infections among men and its impact on HPV related disease in women.

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847554.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098803
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS73638; NLM/ PMC4366004
  •  go-up   go-down


10. Palefsky JM: Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health; 2010 Apr;46(4 Suppl):S12-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related disease in men: not just a women's issue.
  • The most common cause of mortality related to human papillomavirus (HPV) infection is cervical cancer.
  • HPV is associated with a variety of cancers in men, including anal cancer and a subset of penile and oral cancers.
  • The incidence of anal and oral cancers related to HPV is increasing in the general population and is growing even faster among individuals who are immunocompromised because of human immunodeficiency virus (HIV) infection.
  • Likewise, anal HPV infection and anal intraepithelial neoplasia are very common throughout a wide range of ages in both HIV-negative and HIV-positive men who have sex with men.
  • Other HPV-related diseases of clinical importance in men include condylomata acuminata (genital warts) and recurrent respiratory papillomatosis.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Men's Health.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Aug 1;190(3):468-76 [15243918.001]
  • [Cites] Sex Transm Dis. 2004 Oct;31(10):601-7 [15388997.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Int J Cancer. 1989 Aug 15;44(2):199-203 [2547727.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] J Med Virol. 1991 Mar;33(3):159-64 [1652616.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43 [18708396.001]
  • [Cites] J Infect Dis. 2008 Sep 15;198(6):827-35 [18657037.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2683-91 [18843010.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2883-91 [18980292.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):59-70 [19050387.001]
  • [Cites] J Infect Dis. 2009 Jan 1;199(1):7-13 [19086813.001]
  • [Cites] J Adolesc Health. 2009 Jan;44(1):33-40 [19101456.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1251-7 [19089913.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):536-46 [19191636.001]
  • [Cites] World J Urol. 2009 Apr;27(2):141-50 [18607597.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1710-6 [16030106.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41(5):612-20 [16080082.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2550-6 [16284377.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33 [16492924.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2645-54 [16790697.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]
  • [Cites] Emerg Infect Dis. 2007 Jan;13(1):28-41 [17370513.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] Pediatr Infect Dis J. 2007 Mar;26(3):201-9 [17484215.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1128-36 [17955430.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1322-8 [17923869.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] J Infect Dis. 2008 Apr 1;197(7):957-66 [18429348.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Emerg Infect Dis. 2008 Jun;14(6):888-94 [18507898.001]
  • [Cites] Sex Transm Infect. 2008 Jun;84(3):161-6 [18339658.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):345-52 [10888420.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):189-93 [11144896.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):57-69 [11192901.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):705-11 [11875730.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1467-74 [19443352.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1135-42 [19390418.001]
  • [Cites] BMJ. 2009;339:b3884 [19815582.001]
  • [Cites] MMWR CDC Surveill Summ. 1992 Apr 24;41(2):1-7 [1594012.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1666-9 [8348498.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] Acta Derm Venereol. 1995 Nov;75(6):470-4 [8651027.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1060-7 [8683637.001]
  • [Cites] Int J STD AIDS. 1996 May-Jun;7(3):197-200 [8799782.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):353-61 [9237700.001]
  • [Cites] Sex Transm Dis. 1997 Nov;24(10):567-72 [9383844.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):744-54 [15599852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):606-16 [15825185.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):351-7 [12196743.001]
  • [Cites] Sex Transm Infect. 2002 Jun;78(3):215-8 [12238658.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Infect Dis. 2003 Apr 1;187(7):1064-70 [12660920.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] J Infect Dis. 2004 Feb 15;189(4):677-85 [14767822.001]
  • [Cites] Med Microbiol Immunol. 2004 Feb;193(1):35-44 [12838415.001]
  • [ErratumIn] J Adolesc Health. 2010 Jun;46(6):614
  • (PMID = 20307839.001).
  • [ISSN] 1879-1972
  • [Journal-full-title] The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • [ISO-abbreviation] J Adolesc Health
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA054053-10; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / CA088739-05; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA088739-05; United States / NCI NIH HHS / CA / R01 CA054053-10
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS180665; NLM/ PMC2871537
  •  go-up   go-down


11. Jong E, van Gorp EC, Mulder JW, Tol A, Smits PH: Effect of HIV viral load, CD4 cell count and antiretroviral therapy on human papillomavirus prevalence in urine samples of HIV-infected men. Int J STD AIDS; 2009 Apr;20(4):262-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-infected patients are at increased risk for persistent human papillomavirus (HPV) infection, the major cause of anogenital cancer.
  • Further prospective studies are needed to determine the role of HPV DNA testing in urine in future screening programmes for anal cancer in men.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / urine. Anti-Retroviral Agents / therapeutic use. HIV Infections / drug therapy. HIV Infections / immunology. Papillomavirus Infections / epidemiology. Papillomavirus Infections / urine

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304972.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / DNA, Viral; 0 / Reverse Transcriptase Inhibitors
  •  go-up   go-down


12. Gillison ML: Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol; 2009 Sep;21(5):439-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection.
  • PURPOSE OF REVIEW: Oral human papillomavirus (HPV) infection is the principal cause of a distinct form of oropharyngeal cancer (OPCA) that has been rising in incidence in the United States since 1973, particularly among young men.
  • RECENT FINDINGS: Incidence rates for HPV-related OPCA increased with age and were strongly influenced by year of birth in the United States (cohort effect).
  • Persons with HIV/AIDS are at increased risk ( approximately two to six-fold) for OPCA relative to the general population.
  • Consistent with a viral attribution, however, is the apparent increase in risk of OPCA with severity of AIDS-related immunosuppression.
  • Analogous to other HPV-related cancers (e.g. cervical and anal cancer), trends over time do not appear to be influenced by highly active antiretroviral (HAART) therapy.
  • SUMMARY: Healthcare providers may encounter HPV-related OPCA more frequently among individuals with HIV/AIDS as this population ages and due to the strong birth cohort effects observed in the general population.
  • However, there is no evidence in support of different incidence trends over time among persons with and without HIV/AIDS.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587593.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


13. Piketty C, Kazatchkine MD: Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Curr HIV/AIDS Rep; 2005 Aug;2(3):140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy.
  • HIV-infected men who have sex with men remain at high risk of developing anal cancer despite the widespread use of highly active antiretroviral therapy (HAART).
  • In HIV-infected women, however, there is some evidence that HAART may be associated with regression of human papillomavirus (HPV)-related cervical disease.
  • So far, epidemiologic data provided by cancer registries have shown no reduction in the incidence of cervical and anal cancer in patients with HIV infection since the initiation of HAART in 1996.
  • Recent data suggest that HPV infection occurs in the anal canal of immunocompromised patients, as an opportunistic infection, in the absence of receptive anal intercourse.
  • Taken together, these lines of evidence support the need for developing anal and cervical cancer screening programs for patients with HIV, whether untreated or on HAART.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / virology. Cervical Intraepithelial Neoplasia / virology. HIV Infections / drug therapy. Neoplasms, Squamous Cell / virology. Papillomaviridae / pathogenicity. Papillomavirus Infections / etiology


14. Potthoff A, Brockmeyer NH: [HIV-associated tumors]. Hautarzt; 2006 Nov;57(11):988, 990-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the beginning of the HIV epidemic, Kaposi sarcoma was a common stigma in AIDS patients and one of the leading causes of death.
  • The incidence of HPV-related anal carcinoma and its precursor lesions is rising so dramatically that screening programs as they are already established for cervical carcinoma should be implemented.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Antiretroviral Therapy, Highly Active. Anus Neoplasms / etiology. Carcinoma, Hepatocellular / etiology. Female. HIV Seropositivity / complications. Humans. Liver Neoplasms / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Male. Middle Aged. Papillomavirus Infections / complications. Risk Factors. Skin Neoplasms / etiology. Smoking / adverse effects. Uterine Cervical Neoplasms / etiology


15. Coiras M, López-Huertas MR, Mateos E, Alcamí J: Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits IkappaBalpha and enhances HIV-1 replication in human T lymphocytes. Retrovirology; 2008;5:109
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the opposite situation has also been described and the production of a carboxy-terminal fragment that contains two potent transactivation domains has also been related to the onset of apoptosis.
  • Moreover, DeltaNH2p65 was increased in the nuclei of PMA-, PHA-, and TNFalpha-activated T cells, proving this phenomenon was related to cell activation.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3776-83 [11729181.001]
  • [Cites] Retrovirology. 2007;4:56 [17686171.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):10934-41 [12551910.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23094-100 [12686541.001]
  • [Cites] Apoptosis. 2003 Aug;8(4):363-70 [12815279.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1563-74 [12820969.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5530-9 [14532125.001]
  • [Cites] J Immunol. 2004 Mar 15;172(6):3480-90 [15004148.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):107-13 [15226358.001]
  • [Cites] J Immunol. 2004 Nov 1;173(9):5425-33 [15494489.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cell. 1978 Jul;14(3):725-31 [210957.001]
  • [Cites] Science. 1983 Aug 5;221(4610):551-3 [6306768.001]
  • [Cites] J Virol. 1986 Aug;59(2):284-91 [3016298.001]
  • [Cites] Nature. 1987 Apr 16-22;326(6114):711-3 [3031512.001]
  • [Cites] J Virol. 1989 Nov;63(11):4919-24 [2795721.001]
  • [Cites] Nature. 1991 Aug 22;352(6337):733-6 [1876189.001]
  • [Cites] Mol Cell Biol. 1992 Jul;12(7):3094-106 [1620118.001]
  • [Cites] J Virol. 1993 Jan;67(1):288-93 [8416374.001]
  • [Cites] Science. 1993 Mar 19;259(5102):1749-54 [8096089.001]
  • [Cites] J Virol. 1993 Nov;67(11):6596-604 [8411362.001]
  • [Cites] EMBO J. 1993 Sep;12(9):3551-8 [8253080.001]
  • [Cites] Science. 1999 Nov 12;286(5443):1353-7 [10558989.001]
  • [Cites] Nat Cell Biol. 1999 Aug;1(4):227-33 [10559921.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1879-90 [10601362.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1891-6 [10601363.001]
  • [Cites] Annu Rev Immunol. 2000;18:665-708 [10837072.001]
  • [Cites] Eur J Biochem. 2000 Jun;267(12):3828-35 [10849002.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Sep 15;80(2):111-22 [11038244.001]
  • [Cites] J Clin Invest. 2001 Jan;107(2):143-51 [11160127.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):241-6 [11160144.001]
  • [Cites] Int J Oncol. 2001 May;18(5):1077-83 [11295059.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24638-44 [11320092.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 3;285(5):1192-9 [11478781.001]
  • [Cites] J Biol Chem. 1994 Mar 4;269(9):6320-4 [8119981.001]
  • [Cites] Mol Cell Biol. 1995 Apr;15(4):2166-72 [7891711.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1552-60 [7729429.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):17601-4 [8663611.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13459-62 [9153186.001]
  • [Cites] Semin Cancer Biol. 1997 Apr;8(2):63-73 [9299584.001]
  • [Cites] Semin Cancer Biol. 1997 Apr;8(2):75-82 [9299585.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):410-3 [9450761.001]
  • [Cites] J Exp Med. 1998 Feb 16;187(4):587-600 [9463409.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):882-6 [9500443.001]
  • [Cites] Eur J Immunol. 1998 Mar;28(3):891-900 [9541584.001]
  • [Cites] Exp Cell Res. 1998 Oct 10;244(1):302-9 [9770373.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1581-8 [10102628.001]
  • [Cites] J Biol Chem. 1999 Jul 2;274(27):18981-8 [10383397.001]
  • [Cites] J Immunol. 1999 Jul 15;163(2):590-8 [10395645.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):857-60 [15569692.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):24153-8 [15845545.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6111-9 [16024612.001]
  • [Cites] Proteomics. 2006 Apr;6 Suppl 1:S63-73 [16526095.001]
  • [Cites] J Med Virol. 2007 Feb;79(2):127-37 [17177310.001]
  • [Cites] J Am Soc Nephrol. 2002 Dec;13(12):2840-9 [12444202.001]
  • (PMID = 19046417.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / Transcription Factor RelA; 139874-52-5 / NF-kappaB inhibitor alpha; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2631510
  •  go-up   go-down


16. McRee AL, Reiter PL, Chantala K, Brewer NT: Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability? Cancer Epidemiol Biomarkers Prev; 2010 Aug;19(8):1937-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability?
  • We conducted an experiment to see whether framing HPV vaccination as also preventing cancer in men would increase men's vaccination willingness.
  • In the within-subjects experiment, men read four randomly ordered vignettes that described hypothetical vaccines that prevented either genital warts alone, or genital warts and either anal cancer, oral cancer, or penile cancer.
  • RESULTS: Although only 42% of men were willing to receive HPV vaccine when it was framed as preventing genital warts alone, 60% were willing to get it when it was framed as preventing cancer in addition to genital warts (P < 0.001).
  • The effect of outcome framing was the same for heterosexual and gay/bisexual men and for the three cancer types examined.
  • CONCLUSIONS: Men may be more accepting of HPV vaccine when it is framed as preventing cancer, regardless which of the three most common HPV-related cancers in men is described.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10 [16949995.001]
  • [Cites] Health Psychol. 2007 Mar;26(2):136-45 [17385964.001]
  • [Cites] Prev Med. 2007 Aug-Sep;45(2-3):107-14 [17628649.001]
  • [Cites] Health Psychol. 2007 Nov;26(6):745-52 [18020847.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):115-8 [17952620.001]
  • [Cites] Ann Behav Med. 2008 Apr;35(2):221-9 [18347893.001]
  • [Cites] J Am Coll Health. 2008 Jul-Aug;57(1):23-32 [18682342.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1872-9 [18708374.001]
  • [Cites] J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7 [18809147.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K17-28 [18847554.001]
  • [Cites] Sex Transm Dis. 2009 Jan;36(1):58-62 [18830138.001]
  • [Cites] J Am Board Fam Med. 2009 Jan-Feb;22(1):34-42 [19124631.001]
  • [Cites] J Womens Health (Larchmt). 2009 Feb;18(2):225-33 [19183094.001]
  • [Cites] J Behav Med. 2010 Aug;33(4):274-81 [20162346.001]
  • [Cites] Am J Mens Health. 2011 Jul;5(4):297-305 [20798149.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):363-72 [19190161.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Psychol Bull. 1992 Jul;112(1):155-9 [19565683.001]
  • [Cites] Soc Sci Med. 2009 Aug;69(3):475-80 [19540642.001]
  • [Cites] J Adolesc Health. 2010 Feb;46(2):113-23 [20113917.001]
  • [Cites] Sex Transm Dis. 2010 Mar;37(3):197-203 [20118831.001]
  • [Cites] Prev Med. 2010 Apr;50(4):213-4 [20153358.001]
  • [Cites] Sex Transm Infect. 2010 Jun;86(3):241-6 [19951936.001]
  • [Cites] AIDS Patient Care STDS. 1999 Dec;13(12):717-30 [10743535.001]
  • [Cites] Health Commun. 2003;15(4):375-92 [14527864.001]
  • [Cites] J Pers Soc Psychol. 1986 Dec;51(6):1173-82 [3806354.001]
  • [Cites] Health Psychol. 1993 Jul;12(4):324-33 [8404807.001]
  • [Cites] Psychol Bull. 1997 Jan;121(1):3-19 [9000890.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Adolesc Health. 2005 Sep;37(3):179-86 [16109336.001]
  • [Cites] Pediatrics. 2006 May;117(5):1486-93 [16651301.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • (PMID = 20647398.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057726-19; United States / NCI NIH HHS / CA / R25 CA057726; United States / NCI NIH HHS / CA / R25 CA057726-19; United States / NCI NIH HHS / CA / R25 CA57726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS212838; NLM/ PMC2919615
  •  go-up   go-down


17. Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW: Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl); 2005 Sep;181(2):237-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE: Oral Delta-9-tetrahydrocannabinol (Delta(9)-THC; Marinol) is medically available for the treatment of nausea associated with cancer chemotherapy and for wasting syndromes related to HIV/AIDS.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. delta 9-Tetrahydrocannabinol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Biochem Behav. 1994 Nov;49(3):643-7 [7862719.001]
  • [Cites] Neuropsychobiology. 1988;19(2):90-6 [3226529.001]
  • [Cites] Pharmacol Biochem Behav. 1990 Apr;35(4):861-4 [2161109.001]
  • [Cites] Behav Pharmacol. 1997 Jun;8(2-3):101-12 [9833006.001]
  • [Cites] Psychopharmacology (Berl). 1992;107(2-3):255-62 [1319601.001]
  • [Cites] Behav Pharmacol. 1997 Aug;8(4):275-86 [9832987.001]
  • [Cites] Neuropsychopharmacology. 2001 Nov;25(5):757-65 [11682259.001]
  • [Cites] Psychopharmacology (Berl). 2002 Oct;164(1):61-70 [12373420.001]
  • [Cites] Psychopharmacology (Berl). 2002 Jun;161(4):331-9 [12073159.001]
  • [Cites] Neuropsychobiology. 1983;9(4):223-9 [6646394.001]
  • [Cites] J Anal Toxicol. 1993 Sep;17(5):264-72 [8107459.001]
  • [Cites] J Psychoactive Drugs. 1998 Apr-Jun;30(2):187-96 [9692381.001]
  • [Cites] Drug Alcohol Depend. 2003 Jun 5;70(3 Suppl):S41-54 [12759196.001]
  • [Cites] Pharmacol Biochem Behav. 1989 Feb;32(2):483-6 [2542995.001]
  • [Cites] Appetite. 1996 Oct;27(2):165-81 [8937620.001]
  • [Cites] Drug Alcohol Depend. 2000 Jun 1;59(3):251-60 [10812285.001]
  • [Cites] Psychopharmacology (Berl). 1984;83(4):351-6 [6149589.001]
  • [Cites] Drugs Today (Barc). 2004 Aug;40(8):663-76 [15510238.001]
  • [Cites] J Exp Anal Behav. 1994 Mar;61(2):203-11 [8169569.001]
  • [Cites] Exp Clin Psychopharmacol. 1997 Feb;5(1):74-82 [9234042.001]
  • [Cites] Neuropsychopharmacology. 2004 Jan;29(1):158-70 [14560320.001]
  • [Cites] Psychopharmacology (Berl). 2002 Dec;164(4):407-15 [12457271.001]
  • [Cites] Psychopharmacology (Berl). 1995 Mar;118(1):19-27 [7597118.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Mar;3(3):437-40 [12054093.001]
  • [Cites] Psychopharmacology (Berl). 1999 Feb;141(4):385-94 [10090646.001]
  • [Cites] Psychopharmacology (Berl). 1999 Feb;141(4):395-404 [10090647.001]
  • (PMID = 15830233.001).
  • [ISSN] 0033-3158
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA-03746
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Capsules; 0 / Psychotropic Drugs; 7J8897W37S / Dronabinol
  •  go-up   go-down


18. Roma AA, Goldblum JR, Fazio V, Yang B: Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma. Int J Clin Exp Pathol; 2008;1(5):419-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma.
  • 14-3-3sigma is a p53-regulated G2/M inhibitor involved in numerous cellular signaling pathways related to cell cycle, DNA repair and apoptosis.
  • Recent studies have showed that 14-3-3sigma was silenced transcriptionally through promoter hypermethylation mainly in HPV-negative vulvar squamous cell carcinoma (SCC).
  • However, the expression of 14-3-3sigma protein has not yet been studied in anal SCC and its precursor, anal intraepithelial neoplasm (AIN).
  • Fourteen cases of invasive anal SCC were also included in the study, including 8 cases associated with bowenoid AIN and 6 cases associated with differentiated AIN.
  • Weak staining for 14-3-3sigma was seen in anal squamous hyperplasia.
  • In conclusion, two histopathologic types of AIN, bowenoid and differentiated, have distinct immunoprofiles for p16 and p53, which suggests dual molecular pathways during anal carcinogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):429-41 [10716158.001]
  • [Cites] Oncogene. 2000 Nov 2;19(46):5298-302 [11077447.001]
  • [Cites] J Low Genit Tract Dis. 2007 Jan;11(1):46-7 [17194951.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):463-8 [16894294.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4353-7 [10969776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54 [10811911.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):3105-10 [16886641.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):795-801 [16819320.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):183-92 [16697662.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):225-34 [16697215.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):161 [16697214.001]
  • [Cites] Mol Cell Proteomics. 2005 Jun;4(6):785-95 [15778465.001]
  • [Cites] Histopathology. 2005 Jun;46(6):718-20 [15910611.001]
  • [Cites] J Low Genit Tract Dis. 2005 Apr;9(2):108-13 [15870532.001]
  • [Cites] Cell Res. 2005 Apr;15(4):228-36 [15857577.001]
  • [Cites] Pathol Int. 2005 Feb;55(2):77-82 [15693853.001]
  • [Cites] AIDS Read. 2005 Feb;15(2):79-82, 85-6, 88, 91 [15712398.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1477-83 [15619206.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1591-7 [15547695.001]
  • [Cites] Semin Cancer Biol. 1998;8(5):345-57 [10101800.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):3-11 [9659898.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Pathol Int. 2004 Oct;54(10):743-50 [15482563.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1131-8 [15292943.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):206-14 [15213596.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2687-93 [15102672.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1876-81 [11896620.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45193-200 [11577088.001]
  • [Cites] Int J Gynecol Pathol. 2001 Jan;20(1):16-30 [11192069.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • (PMID = 18787619.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480570
  • [Keywords] NOTNLM ; 14-3-3σ / AIN / Anal intraepithelial neoplasm / Bowenoid / differentiated / p16 / p53 / simplex
  •  go-up   go-down


19. Nguyen ML, Farrell KJ, Gunthel CJ: Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era. Curr Infect Dis Rep; 2010 Jan;12(1):46-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era.
  • The introduction of highly active antiretroviral therapy (HAART) has drastically changed the scope and spectrum of diseases associated with HIV, shifting from AIDS-related to non-AIDS-related diseases.
  • Studies linking HIV/AIDS databases to cancer registries have shown a dramatic decrease in AIDS-related malignancies and a steady increase in non-AIDS-defining malignancies (NADM).
  • Meta-analysis of published studies show an increase in NADM over the general population, mostly among infection-related cancers such as anal cancer, Hodgkin lymphoma, and liver cancer.
  • Among the non-infection-related cancers, lung and skin cancers predominate.
  • As HIV-infected individuals survive longer, better screening strategies are needed to detect cancer earlier, and prospective data are needed to assess the impact of HAART on cancer outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Immun Ageing. 2008 Sep 24;5:11 [18816370.001]
  • [Cites] Arch Intern Med. 2009 Jun 22;169(12):1130-8 [19546414.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):3-10 [19339934.001]
  • [Cites] Curr Opin Infect Dis. 2009 Feb;22(1):7-10 [19532075.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Transplant Proc. 2008 Jul-Aug;40(6):1965-71 [18675102.001]
  • [Cites] AIDS. 2009 May 15;23(8):875-85 [19349851.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] AIDS. 2004 Nov 19;18(17):2285-93 [15577541.001]
  • [Cites] Clin Infect Dis. 2009 Oct 1;49(7):1109-16 [19705973.001]
  • [Cites] AIDS. 2008 Apr 23;22(7):841-8 [18427202.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55 [16936558.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):305-9 [19412116.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):432-7 [17307327.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] AIDS Educ Prev. 2009 Jun;21(3 Suppl):3-13 [19537950.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):6-7 [17617251.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1121-6 [17390054.001]
  • [Cites] Arch Intern Med. 2008 Nov 24;168(21):2326-32; discussion 2332 [19029496.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):1-11 [16300854.001]
  • [Cites] Curr Infect Dis Rep. 2009 Sep;11(5):407-13 [19698285.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):527-37 [17692986.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2058-9 [17917974.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):345-50 [19135758.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • (PMID = 21308498.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Jaquenoud Sirot E, van der Velden JW, Rentsch K, Eap CB, Baumann P: Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf; 2006;29(9):735-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The response to medication varies greatly between individuals, according to genetic constitution, age, sex, co-morbidities, environmental factors including diet and lifestyle (e.g. smoking and alcohol intake), and drug-related factors such as pharmacokinetic or pharmacodynamic drug-drug interactions.
  • [MeSH-major] Drug Monitoring / methods. Drug-Related Side Effects and Adverse Reactions. Pharmacogenetics

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Res. 2004 Aug;50(2):195-200 [15177309.001]
  • [Cites] Eur J Clin Pharmacol. 2003 May;59(1):57-64 [12743673.001]
  • [Cites] Arch Gen Psychiatry. 1988 Jan;45(1):79-91 [2892478.001]
  • [Cites] J Psychopharmacol. 2004 Dec;18(4):559-66 [15582923.001]
  • [Cites] Am J Psychiatry. 1998 Sep;155(9):1278-80 [9734555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8170-4 [9653159.001]
  • [Cites] Pharmacogenomics. 2005 Mar;6(2):111-3 [15882130.001]
  • [Cites] Br J Clin Pharmacol. 2001 Oct;52(4):447-50 [11678789.001]
  • [Cites] Am J Psychiatry. 2004 Aug;161(8):1324-33 [15285956.001]
  • [Cites] Pharmacogenetics. 2002 Aug;12(6):465-72 [12172215.001]
  • [Cites] Neuropsychopharmacology. 2002 Jul;27(1):105-19 [12062911.001]
  • [Cites] Clin Pharmacol Ther. 2002 Oct;72(4):429-37 [12386645.001]
  • [Cites] Ther Drug Monit. 2004 Apr;26(2):145-51 [15228155.001]
  • [Cites] Clin Pharmacokinet. 2001;40(9):631-40 [11605713.001]
  • [Cites] Am J Cardiovasc Drugs. 2004;4(5):281-97 [15449971.001]
  • [Cites] Ther Drug Monit. 2005 Aug;27(4):539-43 [16044115.001]
  • [Cites] Clin Pharmacol Ther. 2000 Jun;67(6):684-9 [10872651.001]
  • [Cites] Clin Pharmacol Ther. 2004 May;75(5):386-93 [15116051.001]
  • [Cites] Br J Clin Pharmacol. 1999 Apr;47(4):450-3 [10233212.001]
  • [Cites] Pharmacotherapy. 1998 Mar-Apr;18(2):282-7 [9545147.001]
  • [Cites] Psychopharmacol Bull. 1998;34(4):797-804 [10513455.001]
  • [Cites] Bioethics. 2004 Aug;18(4):303-21 [15449404.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):529-37 [12571261.001]
  • [Cites] Pharmacopsychiatry. 1991 Nov;24(6):190-5 [1812496.001]
  • [Cites] Cell Mol Neurobiol. 1999 Jun;19(3):325-54 [10319191.001]
  • [Cites] Int Clin Psychopharmacol. 1995 Sep;10 Suppl 3:81-5 [8866769.001]
  • [Cites] Am J Psychiatry. 1993 May;150(5):837 [8480837.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Apr;57(1):11-7 [11372584.001]
  • [Cites] Clin Pharmacokinet. 2004;43(1):33-56 [14715050.001]
  • [Cites] Clin Pharmacokinet. 2002;41(5):329-42 [12036391.001]
  • [Cites] Bioethics. 2004 Aug;18(4):361-78 [15449407.001]
  • [Cites] Eur J Clin Pharmacol. 2002 Aug;58(5):321-2 [12185555.001]
  • [Cites] J Clin Psychopharmacol. 2005 Dec;25(6):527-32 [16282832.001]
  • [Cites] Lancet. 1981 Mar 7;1(8219):560-1 [6111662.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1385-91 [15571264.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:453-6 [12505351.001]
  • [Cites] Clin Pharmacol Ther. 2001 Oct;70(4):391-4 [11673755.001]
  • [Cites] J Clin Psychiatry. 1991 Jun;52 Suppl:23-33 [1904862.001]
  • [Cites] Am J Psychiatry. 1985 Feb;142(2):155-62 [3881999.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):465-9 [16126164.001]
  • [Cites] Clin Med Res. 2005 Aug;3(3):137-45 [16160068.001]
  • [Cites] AIDS. 2000 Jun 16;14(9):1291-2 [10894303.001]
  • [Cites] Pharmacogenetics. 1996 Oct;6(5):441-7 [8946476.001]
  • [Cites] Clin Pharmacol Ther. 1999 May;65(5):552-61 [10340921.001]
  • [Cites] Drug Saf. 2004;27(3):145-72 [14756578.001]
  • [Cites] Gene. 1999 Jan 21;226(2):327-38 [9931507.001]
  • [Cites] J Biochem. 1999 Apr;125(4):803-8 [10101295.001]
  • [Cites] J Clin Psychopharmacol. 1997 Jun;17(3):208-21 [9169967.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7403-13 [14576848.001]
  • [Cites] Clin Pharmacol Ther. 2002 Mar;71(3):141-52 [11907488.001]
  • [Cites] Mol Psychiatry. 2004 May;9(5):442-73 [15037866.001]
  • [Cites] Clin Pharmacol Ther. 1996 Aug;60(2):145-56 [8823232.001]
  • [Cites] Drugs Aging. 2001;18(1):45-61 [11232738.001]
  • [Cites] Gastroenterology. 1989 Jan;96(1):11-7 [2909416.001]
  • [Cites] Pharmacogenetics. 1999 Feb;9(1):71-80 [10208645.001]
  • [Cites] Blood Cells Mol Dis. 2003 Jul-Aug;31(1):98-101 [12850492.001]
  • [Cites] J Mol Med (Berl). 2003 Mar;81(3):154-67 [12682724.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1690-8 [11926893.001]
  • [Cites] Pharmacogenetics. 1997 Jun;7(3):187-91 [9241658.001]
  • [Cites] Eur Neuropsychopharmacol. 2002 Jun;12(3):255-60 [12007677.001]
  • [Cites] Eur J Clin Pharmacol. 2004 Jul;60(5):329-36 [15168101.001]
  • [Cites] Clin Pharmacokinet. 1987 Dec;13(6):381-92 [3325215.001]
  • [Cites] Drugs. 2002;62(15):2169-83 [12381217.001]
  • [Cites] Ther Drug Monit. 1996 Aug;18(4):393-6 [8857557.001]
  • [Cites] Clin Pharmacol Ther. 2002 Oct;72(4):438-52 [12386646.001]
  • [Cites] J Clin Psychiatry. 1997 Nov;58(11):499 [9413421.001]
  • [Cites] Biol Pharm Bull. 1999 Jan;22(1):77-9 [9989666.001]
  • [Cites] Psychopharmacology (Berl). 1996 Dec;128(4):421-5 [8986013.001]
  • [Cites] Clin Pharmacol Ther. 1998 Apr;63(4):444-52 [9585799.001]
  • [Cites] J Clin Psychopharmacol. 2000 Apr;20(2):246-51 [10770465.001]
  • [Cites] J Affect Disord. 1985 Jan-Feb;8(1):47-53 [3156911.001]
  • [Cites] Food Chem Toxicol. 2003 Feb;41(2):225-45 [12480299.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2004 Jan;94(1):13-8 [14725610.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Aug;314(2):703-9 [15860574.001]
  • [Cites] Br J Clin Pharmacol. 1995 Apr;39(4):433-9 [7640151.001]
  • [Cites] Crit Rev Toxicol. 1999 Jan;29(1):59-124 [10066160.001]
  • [Cites] Acta Psychiatr Scand. 2001 Sep;104(3):173-92 [11531654.001]
  • [Cites] Drug Metab Dispos. 2001 Sep;29(9):1205-9 [11502729.001]
  • [Cites] Br J Clin Pharmacol. 2001 Mar;51(3):213-7 [11298066.001]
  • [Cites] Pharmacogenomics J. 2002;2(3):191-6 [12082591.001]
  • [Cites] Eur J Clin Pharmacol. 2002 Jul;58(4):285-91 [12136375.001]
  • [Cites] Clin Pharmacokinet. 1995 Jul;29(1):29-35 [7586896.001]
  • [Cites] Am J Psychiatry. 1995 Jul;152(7):1098 [7793452.001]
  • [Cites] Br J Clin Pharmacol. 2002 Feb;53(2):111-22 [11851634.001]
  • [Cites] Br J Clin Pharmacol. 1997 Nov;44(5):439-46 [9384460.001]
  • [Cites] Pharmacogenetics. 2001 Dec;11(9):803-8 [11740344.001]
  • [Cites] Clin Chim Acta. 2002 Jan;315(1-2):137-55 [11728416.001]
  • [Cites] Clin Pharmacokinet. 2004;43(13):845-53 [15509183.001]
  • [Cites] Fundam Clin Pharmacol. 1995;9(5):488-502 [8617413.001]
  • [Cites] Ther Drug Monit. 2005 Oct;27(5):549-57 [16175124.001]
  • [Cites] Aust N Z J Psychiatry. 2004 Jul;38(7):483-9 [15255819.001]
  • [Cites] Clin Pharmacol Ther. 2003 Nov;74(5):437-47 [14586384.001]
  • [Cites] Eur J Pharm Sci. 2003 Dec;20(4-5):439-49 [14659488.001]
  • [Cites] Psychopharmacol Bull. 1997;33(2):235-41 [9230636.001]
  • [Cites] Pharmacogenomics. 2001 Feb;2(1):51-64 [11258197.001]
  • [Cites] Clin Pharmacol Ther. 2001 Nov;70(5):484-92 [11719736.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2827-31 [15625333.001]
  • [Cites] J Clin Psychiatry. 2004 Jun;65(6):766-71 [15291653.001]
  • [Cites] Schizophr Res. 1998 Jul 27;32(2):101-6 [9713905.001]
  • [Cites] Am J Hum Genet. 1997 Feb;60(2):284-95 [9012401.001]
  • [Cites] Clin Pharmacokinet. 2001;40(7):523-37 [11510629.001]
  • [Cites] Chin Med J (Engl). 2002 Dec;115(12):1780-4 [12622923.001]
  • [Cites] Mol Pharmacol. 2003 Sep;64(3):659-69 [12920202.001]
  • [Cites] Crit Care Med. 2004 Feb;32(2):502-8 [14758170.001]
  • [Cites] Pharmacogenetics. 1995 Feb;5(1):37-42 [7773301.001]
  • [Cites] Int Clin Psychopharmacol. 2002 May;17 (3):141-3 [11981356.001]
  • [Cites] J Natl Med Assoc. 2002 Oct;94(10 Suppl):1-26 [12401060.001]
  • [Cites] Pharmacogenetics. 1994 Aug;4(4):193-8 [7987403.001]
  • [Cites] J Clin Psychopharmacol. 2001 Oct;21(5):500-15 [11593076.001]
  • [Cites] Clin Pharmacokinet. 2003;42(1):59-98 [12489979.001]
  • [Cites] Nat Rev Drug Discov. 2005 Nov;4(11):911-8 [16264434.001]
  • [Cites] Dig Liver Dis. 2005 Apr;37(4):282-97 [15788214.001]
  • [Cites] J Clin Psychopharmacol. 1986 Aug;6(4):249-50 [3734148.001]
  • [Cites] Clin Pharmacokinet. 2002;41(11):853-76 [12190332.001]
  • [Cites] J Clin Psychopharmacol. 2005 Aug;25(4 Suppl 1):S19-23 [16027556.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):847-54 [9466980.001]
  • [Cites] JAMA. 1991 Nov 27;266(20):2847-51 [1942452.001]
  • [Cites] Am Rev Tuberc. 1954 Aug;70(2):266-73 [13180863.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 Mar;15(3):179-84 [16184621.001]
  • [Cites] Psychiatr Clin North Am. 1993 Sep;16(3):611-45 [8415237.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1997;391:14-21 [9265947.001]
  • [Cites] Pharmacogenetics. 2003 Mar;13(3):169-72 [12618594.001]
  • [Cites] J Pharmacokinet Biopharm. 1996 Oct;24(5):509-19 [9131488.001]
  • [Cites] Pharmacogenetics. 1999 Aug;9(4):435-43 [10780263.001]
  • [Cites] Pharmacogenetics. 1997 Feb;7(1):59-64 [9110363.001]
  • [Cites] Pharmazie. 2003 Jul;58(7):447-74 [12889529.001]
  • [Cites] Pharmacogenomics J. 2001;1(1):59-64 [11913728.001]
  • [Cites] J Clin Psychopharmacol. 1994 Aug;14(4):230-40 [7962678.001]
  • [Cites] Drug Saf. 2005;28(12):1075-83 [16329711.001]
  • [Cites] Drug Saf. 2003;26(1):13-21 [12495360.001]
  • [Cites] Int Clin Psychopharmacol. 2005 May;20(3):163-8 [15812267.001]
  • [Cites] Drug Saf. 2005;28(3):263-75 [15733030.001]
  • [Cites] J Mol Med (Berl). 2003 Mar;81(3):141-53 [12682723.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:815-50 [11264478.001]
  • [Cites] Pharmacopsychiatry. 1999 Jul;32(4):148-53 [10505485.001]
  • [Cites] J Clin Psychopharmacol. 2005 Apr;25(2):188-91 [15738755.001]
  • [Cites] Pharmacogenomics. 2002 Mar;3(2):229-43 [11972444.001]
  • [Cites] Encephale. 2000 Jan-Feb;26(1):62-7 [10875063.001]
  • [Cites] Clin Pharmacol Ther. 2000 Sep;68(3):231-7 [11014404.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:123-49 [16402901.001]
  • [Cites] Drug Discov Today. 2001 Aug 15;6(16):835-839 [11495756.001]
  • [Cites] Pharmacogenomics J. 2005;5(1):60-9 [15505641.001]
  • [Cites] Clin Pharmacol Ther. 1999 Aug;66(2):185-92 [10460072.001]
  • [Cites] Clin Infect Dis. 2001 Aug 15;33(4):584-5 [11462203.001]
  • [Cites] Br J Clin Pharmacol. 2001;52 Suppl 1:75S-87S [11564055.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):412-7 [10917561.001]
  • [Cites] Pharmacopsychiatry. 2000 May;33(3):112-5 [10855463.001]
  • [Cites] Science. 1999 Oct 15;286(5439):487-91 [10521338.001]
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Pharmacogenetics. 2003 Dec;13(12):767-72 [14646695.001]
  • [Cites] J Clin Psychopharmacol. 2005 Dec;25(6):521-6 [16282831.001]
  • [Cites] Drug Saf. 2005;28(9):789-801 [16119972.001]
  • [Cites] Clin Pharmacol Ther. 1995 Mar;57(3):265-9 [7697944.001]
  • [Cites] Ther Drug Monit. 2000 Feb;22(1):118-21 [10688273.001]
  • [Cites] Ther Drug Monit. 2000 Feb;22(1):114-7 [10688272.001]
  • [Cites] CNS Drug Rev. 2001 Fall;7(3):283-304 [11607044.001]
  • [Cites] J Clin Psychiatry. 1999 Jan;60(1):36-40 [10074876.001]
  • [Cites] Bioethics. 2004 Aug;18(4):344-60 [15449406.001]
  • [Cites] Pharmacogenomics. 2002 May;3(3):349-66 [12052143.001]
  • [Cites] CNS Drugs. 2002;16(5):317-24 [11994021.001]
  • [Cites] Br J Clin Pharmacol. 2001 Feb;51(2):169-73 [11259990.001]
  • [Cites] Ther Drug Monit. 1985;7(4):478-80 [4082245.001]
  • [Cites] Pharmacogenetics. 1994 Apr;4(2):47-57 [8081413.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):65-72 [11998554.001]
  • [Cites] Pharmacogenetics. 1999 Feb;9(1):37-42 [10208641.001]
  • [Cites] Psychiatr Serv. 2005 Jan;56(1):31-3 [15637188.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1493-9 [9893619.001]
  • [Cites] J Clin Psychopharmacol. 2001 Aug;21(4):398-407 [11476124.001]
  • [Cites] Pharmacology. 2000 Feb;60(2):58-73 [10657755.001]
  • [Cites] Int J Neuropsychopharmacol. 2003 Mar;6(1):57-72 [12899737.001]
  • [Cites] Clin Pharmacokinet. 1998 Mar;34(3):227-63 [9533984.001]
  • [Cites] Acta Psychiatr Scand. 2000 May;101(5):354-9 [10823294.001]
  • [Cites] Chirality. 1993;5(6):407-13 [8398598.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):653 [14961555.001]
  • [Cites] J Clin Monit Comput. 1999 Dec;15(7-8):529-44 [12578052.001]
  • [Cites] Oncologist. 2005 Feb;10(2):104-11 [15709212.001]
  • [Cites] Pharmacogenet Genomics. 2005 Jan;15(1):1-5 [15864119.001]
  • [Cites] AAPS PharmSci. 2000;2(3):E29 [11741245.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Feb;38(2):61-8 [10706192.001]
  • [Cites] Br J Clin Pharmacol. 2001;52 Suppl 1:45S-54S [11564052.001]
  • [Cites] Eur J Clin Pharmacol. 1973 Jun;6(1):44-53 [4797180.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):375-83 [11061577.001]
  • [Cites] Int J Neuropsychopharmacol. 2005 Mar;8(1):27-36 [15710053.001]
  • [Cites] J Clin Psychopharmacol. 2000 Feb;20(1):35-42 [10653206.001]
  • [Cites] Ther Drug Monit. 2000 Apr;22(2):143-54 [10774624.001]
  • [Cites] Pharmacotherapy. 1998 Mar-Apr;18(2):392-8 [9545161.001]
  • [Cites] Clin Pharmacol Ther. 2001 Mar;69(3):158-68 [11240980.001]
  • [Cites] Lancet. 2000 Nov 11;356(9242):1667-71 [11089838.001]
  • [Cites] Bull Acad Natl Med. 2003;187(4):647-66; discussion 666-70 [14556474.001]
  • [Cites] Eur J Clin Pharmacol. 1997;53(1):19-22 [9349925.001]
  • [Cites] Ann Pharmacother. 1998 Apr;32(4):432-6 [9562139.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Jul;270(1):414-23 [8035341.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Dec;299(3):825-31 [11714865.001]
  • [Cites] J Clin Psychopharmacol. 2004 Apr;24(2):214-9 [15206669.001]
  • [Cites] Eur J Clin Nutr. 2004 Jan;58(1):1-9 [14679360.001]
  • [Cites] Clin Pharmacokinet. 1998 Nov;35(5):361-90 [9839089.001]
  • [Cites] Am J Clin Dermatol. 2001;2(6):349-51 [11770389.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1816-9 [10961881.001]
  • [Cites] Drug Saf. 2005;28(8):677-94 [16048354.001]
  • [Cites] Br J Clin Pharmacol. 1999 Sep;48(3):409-15 [10510154.001]
  • [Cites] J Clin Pharm Ther. 2000 Oct;25(5):355-61 [11123487.001]
  • [Cites] Pharmacogenetics. 1996 Dec;6(6):547-51 [9014204.001]
  • [Cites] Ther Drug Monit. 2004 Aug;26(4):459-61 [15257079.001]
  • [Cites] Eur Neuropsychopharmacol. 2002 Oct;12(5):433-44 [12208561.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):383-91 [11279519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 [10716719.001]
  • [Cites] Pharmacogenomics J. 2005;5(1):6-13 [15492763.001]
  • [Cites] Am J Pharmacogenomics. 2003;3(1):37-52 [12562215.001]
  • [Cites] J Clin Psychopharmacol. 2002 Aug;22(4):440-1 [12172351.001]
  • [Cites] Neuropsychopharmacology. 2000 Apr;22(4):380-7 [10700657.001]
  • [Cites] Am J Psychiatry. 2004 Jun;161(6):1129 [15169709.001]
  • [Cites] Br J Clin Pharmacol. 2001 Sep;52(3):265-71 [11560558.001]
  • [Cites] J Mol Med (Berl). 2003 Mar;81(3):135-40 [12755119.001]
  • [Cites] Br J Clin Pharmacol. 2003 Sep;56(3):341-4 [12919186.001]
  • [Cites] Commun Psychopharmacol. 1978;2(5):381-91 [738018.001]
  • [Cites] Schweiz Med Wochenschr. 1999 Jun 19;129(24):915-22 [10413826.001]
  • [Cites] Mol Psychiatry. 2000 Jul;5(4):410-7 [10889552.001]
  • [Cites] Ther Drug Monit. 1998 Jun;20(3):243-7 [9631918.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Oct;14(10):960-6 [10530490.001]
  • [Cites] J Pharmacol Exp Ther. 1967 Sep;157(3):503-8 [6048010.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Jan;316(1):336-48 [16192315.001]
  • [Cites] J Clin Psychiatry. 1994 Dec;55 Suppl:38-45; discussion 46-7 [7814357.001]
  • [Cites] Int J Clin Pharmacol Ther. 1999 Nov;37(11):529-47 [10584975.001]
  • [Cites] Pharmacopsychiatry. 2004 Nov;37(6):243-65 [15551191.001]
  • [Cites] J R Soc Med. 1999 Sep;92(9):474-5 [10645303.001]
  • [Cites] JAMA. 2001 Nov 14;286(18):2270-9 [11710893.001]
  • [Cites] Clin Pharmacokinet. 2003;42(13):1071-88 [14531721.001]
  • [Cites] Pharmacopsychiatry. 1998 Sep;31(5):163-9 [9832347.001]
  • [Cites] BMJ. 2004 Jul 3;329(7456):15-9 [15231615.001]
  • [Cites] JAMA. 1997 Jan 22-29;277(4):307-11 [9002493.001]
  • [Cites] Biol Psychiatry. 1998 Oct 15;44(8):733-8 [9798077.001]
  • [Cites] Pharmacopsychiatry. 2003 May;36(3):98-104 [12806567.001]
  • [Cites] Clin Pharmacol Ther. 2005 Dec;78(6):582-92 [16338274.001]
  • [Cites] Ther Drug Monit. 2004 Apr;26(2):186-91 [15228163.001]
  • [Cites] J Clin Psychopharmacol. 2003 Apr;23 (2):119-27 [12640212.001]
  • [Cites] Ther Drug Monit. 2004 Aug;26(4):366-74 [15257065.001]
  • [Cites] CNS Drugs. 2003;17(3):143-51 [12617694.001]
  • [Cites] Ther Drug Monit. 1995 Feb;17(1):33-8 [7725374.001]
  • [Cites] Drug Metab Rev. 2003 Nov;35(4):417-54 [14705869.001]
  • [Cites] Pharmacogenomics. 2004 Jul;5(5):571-9 [15212593.001]
  • [Cites] Med Sci Monit. 2004 Jan;10(1):RA5-14 [14704647.001]
  • [Cites] J Clin Psychopharmacol. 2005 Oct;25(5):448-56 [16160620.001]
  • [Cites] Clin Neurosci. 1995;3(2):112-21 [7583617.001]
  • [Cites] Nat Rev Drug Discov. 2005 Oct;4(10):825-33 [16224454.001]
  • [Cites] Trends Pharmacol Sci. 2001 Jun;22(6):298-305 [11395158.001]
  • [Cites] J Clin Psychopharmacol. 2000 Dec;20(6):708-10 [11106150.001]
  • [Cites] Psychopharmacol Bull. 1996;32(2):253-7 [8783895.001]
  • [Cites] Lancet. 1977 Sep 17;2(8038):584-6 [71400.001]
  • [Cites] Br J Psychiatry. 1997 Jan;170:23-6 [9068770.001]
  • [Cites] Clin Pharmacokinet. 1997 Mar;32(3):210-58 [9084960.001]
  • [Cites] Clin Pharmacol Ther. 2005 Dec;78(6):593-604 [16338275.001]
  • [Cites] Biol Pharm Bull. 2002 Nov;25(11):1391-400 [12419946.001]
  • [Cites] Psychiatr Serv. 2004 May;55(5):491-3 [15128955.001]
  • [Cites] Br J Clin Pharmacol. 1999 Apr;47(4):445-9 [10233211.001]
  • [Cites] Ann Pharmacother. 2002 Sep;36(9):1331-6 [12196047.001]
  • [Cites] J Intern Med. 2001 Sep;250(3):186-200 [11555122.001]
  • [Cites] J Pharm Biomed Anal. 2004 Sep 3;35(5):1203-12 [15336365.001]
  • [Cites] Lancet. 1999 Feb 27;353(9154):717-9 [10073515.001]
  • [Cites] Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7 [11704898.001]
  • [Cites] Drug Saf. 2003;26(5):353-62 [12650635.001]
  • [Cites] Drug Metab Rev. 1999 May;31(2):545-60 [10335452.001]
  • [Cites] Ann Intern Med. 1998 Dec 15;129(12 ):1027-30 [9867757.001]
  • [Cites] Drug Saf. 2001;24(2):75-85 [11235820.001]
  • [Cites] Eur Neuropsychopharmacol. 2003 Oct;13(5):381-5 [12957337.001]
  • [Cites] Br J Clin Pharmacol. 1998 Jun;45(6):525-38 [9663807.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Apr;57(1):47-9 [11372590.001]
  • [Cites] Pharmacogenetics. 2001 Jul;11(5):429-35 [11470995.001]
  • [Cites] Clin Pharmacokinet. 1995 Dec;29(6):442-50 [8787949.001]
  • [Cites] Clin Pharmacokinet. 2002;41(14):1153-93 [12405865.001]
  • [Cites] Bioethics. 2004 Aug;18(4):322-42 [15449405.001]
  • [Cites] Clin Pharmacol Ther. 1996 Nov;60(5):522-34 [8941025.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1200-5 [9555760.001]
  • [Cites] Eur J Clin Pharmacol. 2004 Jun;60(4):231-6 [15114431.001]
  • [Cites] Pharmacogenetics. 2001 Feb;11(1):45-55 [11207030.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):821-8 [11191886.001]
  • [Cites] Clin Pharmacokinet. 2005;44(1):33-60 [15634031.001]
  • [Cites] Eur J Pharmacol. 2003 Jul 25;473(2-3):197-206 [12892839.001]
  • [Cites] J Biochem Biophys Methods. 2001 Jan 30;47(1-2):151-7 [11179771.001]
  • [Cites] Clin Chem. 2005 Feb;51(2):376-85 [15590749.001]
  • [Cites] Ther Drug Monit. 2003 Feb;25(1):54-60 [12548145.001]
  • [Cites] Clin Pharmacokinet. 1991 Jun;20(6):447-62 [2044329.001]
  • [Cites] Arch Intern Med. 1995 Oct 9;155(18):1949-56 [7575048.001]
  • [Cites] Drug Metab Dispos. 2000 Oct;28(10 ):1176-83 [10997936.001]
  • [Cites] Br J Clin Pharmacol. 1999 Feb;47(2):131-43 [10190647.001]
  • [Cites] Eur J Clin Pharmacol. 2001 May;57(2):123-7 [11417443.001]
  • [Cites] JAMA. 1997 Jan 22-29;277(4):301-6 [9002492.001]
  • [Cites] Clin Pharmacol Ther. 2002 Dec;72 (6):702-10 [12496751.001]
  • [Cites] J Clin Psychopharmacol. 1998 Aug;18(4):311-6 [9690697.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:535-67 [11264468.001]
  • [Cites] Clin Pharmacokinet. 2002;41(7):453-70 [12083975.001]
  • [Cites] Br J Clin Pharmacol. 2001;52 Suppl 1:21S-34S [11564050.001]
  • [Cites] J Clin Pharm Ther. 2000 Jun;25(3):197-220 [10886465.001]
  • [Cites] Clin Pharmacol Ther. 1992 Apr;51(4):388-97 [1345344.001]
  • [Cites] Eur J Clin Pharmacol. 1999 Feb;54(12):895-902 [10192748.001]
  • [Cites] Pharmacogenetics. 1995 Apr;5(2):64-71 [7663530.001]
  • [Cites] Drug Metab Dispos. 1997 Dec;25(12):1379-82 [9394027.001]
  • [Cites] Am J Transplant. 2004 Dec;4(12):2126-31 [15575918.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2211-21 [15917386.001]
  • [Cites] Clin Infect Dis. 2001 Nov 1;33(9):1595-7 [11568856.001]
  • [Cites] Psychosomatics. 2005 May-Jun;46(3):274-5 [15883150.001]
  • [Cites] Commun Psychopharmacol. 1978;2(5):373-80 [738017.001]
  • [Cites] Ther Drug Monit. 1997 Oct;19(5):543-4 [9357099.001]
  • [Cites] Bioethics. 2004 Aug;18(4):iii-viii [15449403.001]
  • [Cites] Clin Pharmacol Ther. 2004 Aug;76(2):178-84 [15289794.001]
  • [Cites] Ther Drug Monit. 2004 Apr;26(2):156-60 [15228157.001]
  • [Cites] Pharmacology. 2000 Sep;61(3):154-66 [10971201.001]
  • [Cites] Ther Drug Monit. 1995 Dec;17 (6):690-9 [8588243.001]
  • [Cites] Int J Neuropsychopharmacol. 2002 Sep;5(3):255-75 [12366879.001]
  • [Cites] Environ Mol Mutagen. 2000;36(3):221-7 [11044903.001]
  • [Cites] Clin Pharmacokinet. 2001;40(11):783-802 [11735602.001]
  • [Cites] Clin Pharmacokinet. 1992 Aug;23 (2):132-46 [1511529.001]
  • [Cites] J Clin Psychopharmacol. 2005 Dec;25(6):570-4 [16282840.001]
  • [Cites] Pharmacopsychiatry. 2006 Jul;39(4):150-2 [16871470.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Br Med J. 1971 Aug 7;3(5770):331-4 [5558186.001]
  • [Cites] Clin Pharmacokinet. 2002;41(4):235-53 [11978143.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Aug 10;18(12):825-34 [12201904.001]
  • [Cites] Int J Neuropsychopharmacol. 1998 Dec;1(2):173-185 [11281961.001]
  • [Cites] Lancet. 2000 Oct 7;356(9237):1255-9 [11072960.001]
  • [Cites] J Clin Psychopharmacol. 1998 Feb;18(1):2-9 [9472836.001]
  • [Cites] Nat Rev Drug Discov. 2005 Aug;4(8):639-47 [16056390.001]
  • [Cites] Br Med J. 1969 Dec 27;4(5686):764-8 [5391106.001]
  • [Cites] Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S235-43 [14677085.001]
  • [Cites] Ther Drug Monit. 2003 Dec;25(6):700-8 [14639056.001]
  • [Cites] Fundam Clin Pharmacol. 2005 Oct;19(5):511-29 [16176329.001]
  • [Cites] Ther Drug Monit. 1995 Dec;17(6):606-14 [8588229.001]
  • [Cites] J Clin Psychiatry. 2005 Jan;66(1):15-27 [15669884.001]
  • [Cites] Ther Drug Monit. 2004 Apr;26(2):227-30 [15228170.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):436 [8094196.001]
  • [Cites] Ther Drug Monit. 1995 Dec;17(6):676-80 [8588240.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):538-49 [12571262.001]
  • [Cites] Int J Neuropsychopharmacol. 2000 Mar;3(1):55-60 [11343579.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9 [9840430.001]
  • [Cites] Adv Pharmacol. 1997;43:7-35 [9342171.001]
  • (PMID = 16944962.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 348
  •  go-up   go-down


22. Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, Yagita H, Lifson JD, Shearer GM: CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood; 2005 Nov 15;106(10):3524-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently reported that plasma levels of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) are elevated in HIV-1-infected patients and that they correlate with viral load.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2002 Aug;76(16):8433-45 [12134046.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1365-72 [9334376.001]
  • [Cites] J Virol. 2003 Jun;77(12):6700-8 [12767990.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):516-23 [12872134.001]
  • [Cites] Nat Immunol. 2003 Sep;4(9):825-6 [12942081.001]
  • [Cites] J Neuroimmunol. 2004 Mar;148(1-2):127-39 [14975593.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Feb;20(2):175-82 [15018705.001]
  • [Cites] Curr HIV Res. 2003 Oct;1(4):405-17 [15049427.001]
  • [Cites] Immunogenetics. 2004 Apr;56(1):56-60 [15042330.001]
  • [Cites] J Virol. 2004 May;78(10):5223-32 [15113904.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):761-70 [15365095.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):749-59 [15365096.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Feb;83(3):772-6 [3003749.001]
  • [Cites] J Interferon Res. 1986 Apr;6(2):143-52 [2425014.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Science. 1989 Jul 21;245(4915):305-8 [2665081.001]
  • [Cites] Immunity. 1997 Dec;7(6):821-30 [9430227.001]
  • [Cites] Eur J Immunol. 1998 Jan;28(1):143-52 [9485194.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]
  • [Cites] J Virol. 2001 Feb;75(3):1152-64 [11152488.001]
  • [Cites] J Exp Med. 2001 Mar 5;193(5):651-60 [11238596.001]
  • [Cites] Blood. 2001 Aug 15;98(4):906-12 [11493432.001]
  • [Cites] AIDS. 2001 Sep 7;15(13):1603-12 [11546934.001]
  • [Cites] Cytometry. 2001 Sep 1;45(1):37-46 [11598945.001]
  • [Cites] J Virol. 2001 Nov;75(22):11128-36 [11602752.001]
  • [Cites] Eur J Immunol. 2001 Dec;31(12):3513-24 [11745371.001]
  • [Cites] Immunobiology. 2001 Dec;204(5):629-38 [11846228.001]
  • [Cites] Nat Med. 2002 Apr;8(4):319-23 [11927927.001]
  • [Cites] J Exp Med. 1998 Apr 6;187(7):1113-22 [9529327.001]
  • [Cites] J Virol. 1998 Oct;72(10):7992-8001 [9733838.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S311-9 [9814959.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2639-47 [10072506.001]
  • [Cites] Nat Med. 1999 Mar;5(3):344-6 [10086394.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):358-70 [10096580.001]
  • [Cites] J Exp Med. 1999 May 3;189(9):1451-60 [10224285.001]
  • [Cites] Blood. 1999 May 15;93(10):3309-16 [10233883.001]
  • [Cites] Science. 1999 Jun 11;284(5421):1835-7 [10364556.001]
  • [Cites] J Virol. 2005 Mar;79(5):3195-9 [15709041.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2458-64 [15585654.001]
  • [Cites] J Exp Med. 1992 Feb 1;175(2):331-40 [1346269.001]
  • [Cites] J Virol. 1993 Apr;67(4):2182-90 [8445728.001]
  • [Cites] Science. 1993 Mar 19;259(5102):1749-54 [8096089.001]
  • [Cites] Nat Med. 1995 Feb;1(2):129-34 [7585008.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2456-63 [9036997.001]
  • [Cites] Science. 1997 Apr 4;276(5309):111-3 [9082980.001]
  • [Cites] Virology. 1997 Mar 31;230(1):134-44 [9126269.001]
  • [Cites] Science. 1997 Aug 8;277(5327):768 [9273698.001]
  • [Cites] J Infect Dis. 1997 Sep;176(3):811-4 [9291341.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):611-21 [12697854.001]
  • (PMID = 16046522.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antibodies; 0 / Apoptosis Regulatory Proteins; 0 / HIV Envelope Protein gp120; 0 / Interferon Type I; 0 / Membrane Glycoproteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1895067
  •  go-up   go-down


23. Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, Parniak MA, Crouch RJ, McMahon JB, Beutler JA, Le Grice SF: Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res; 2005;33(4):1249-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-throughput screening of a National Cancer Institute library of pure natural products identified the hydroxylated tropolone derivatives beta-thujaplicinol (2,7-dihydroxy-4-1(methylethyl)-2,4,6-cycloheptatrien-1-one) and manicol (1,2,3,4-tetrahydro-5-7-dihydroxy-9-methyl-2-(1-methylethenyl)-6H-benzocyclohepten-6-one) as potent and selective inhibitors of the ribonuclease H (RNase H) activity of human immunodeficiency virus-type 1 reverse transcriptase (HIV-1 RT).
  • In contrast, the related tropolone analog beta-thujaplicin (2-hydroxy-4-(methylethyl)-2,4,6-cycloheptatrien-1-one), which lacks the 7-OH group of the heptatriene ring, was inactive, while manicol, which possesses a 7-OH group, inhibited HIV-1 and E.coli RNases H with IC50 = 1.5 microM and 40 microM, respectively.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 1981 Mar 16;115(1):207-16 [7227366.001]
  • [Cites] Chembiochem. 2004 Apr 2;5(4):527-33 [15185377.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] J Antibiot (Tokyo). 1988 Jul;41(7):862-8 [3417559.001]
  • [Cites] J Chromatogr. 1988 Nov 25;455:430-3 [3235623.001]
  • [Cites] J Gen Virol. 1991 Jan;72 ( Pt 1):59-66 [1703563.001]
  • [Cites] Science. 1991 Apr 5;252(5002):88-95 [1707186.001]
  • [Cites] J Med Chem. 1992 Jul 24;35(15):2735-43 [1379639.001]
  • [Cites] J Virol. 1993 Apr;67(4):2412-20 [7680393.001]
  • [Cites] J Biol Chem. 1994 Mar 25;269(12):8803-7 [8132614.001]
  • [Cites] Bioorg Med Chem. 1994 Mar;2(3):169-79 [7522907.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4861-9 [7533167.001]
  • [Cites] Biochemistry. 1996 Feb 13;35(6):1911-7 [8639674.001]
  • [Cites] Biochemistry. 1997 Mar 18;36(11):3179-85 [9115994.001]
  • [Cites] Antiviral Res. 1998 Aug;39(2):89-100 [9806486.001]
  • [Cites] Biochemistry. 1999 Oct 5;38(40):13070-6 [10529177.001]
  • [Cites] Anal Biochem. 2004 Aug 15;331(2):296-302 [15265735.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2000 Feb;48(2):194-200 [10705503.001]
  • [Cites] J Biol Inorg Chem. 2000 Feb;5(1):67-74 [10766438.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):995-7 [10963310.001]
  • [Cites] Adv Pharmacol. 2000;49:67-109 [11013761.001]
  • [Cites] Biochemistry. 2000 Nov 21;39(46):14279-91 [11087377.001]
  • [Cites] Methods Mol Biol. 2001;160:335-54 [11265294.001]
  • [Cites] Anal Biochem. 2001 Apr 15;291(2):198-206 [11401293.001]
  • [Cites] Phytother Res. 2001 Nov;15(7):586-8 [11746838.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16689-96 [11875059.001]
  • [Cites] Biol Pharm Bull. 2002 Aug;25(8):981-5 [12186430.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2777-80 [12480948.001]
  • [Cites] AIDS Rev. 2002 Oct-Dec;4(4):183-94 [12555693.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):807-15 [12667461.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5776-88 [14500841.001]
  • [Cites] Biol Pharm Bull. 2003 Oct;26(10):1487-90 [14519960.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 1;31(23):6852-9 [14627818.001]
  • [Cites] Anal Biochem. 2003 Nov 1;322(1):33-9 [14705777.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4757-63 [14981923.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1539-47 [15004241.001]
  • [Cites] Methods Enzymol. 1982;87:500-9 [6757651.001]
  • (PMID = 15741178.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Benzocycloheptenes; 0 / Coumarins; 0 / Pyranocoumarins; 0 / Reverse Transcriptase Inhibitors; 0 / beta-thujaplicinol; 0 / manicol; 7L6DL16P1T / Tropolone; EC 3.1.26.4 / Ribonuclease H; S5A9TQN46W / calanolide A
  • [Other-IDs] NLM/ PMC552956
  •  go-up   go-down


24. Palefsky J: Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS; 2009 Jan;4(1):52-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related disease in people with HIV.
  • PURPOSE OF REVIEW: The incidence of human papillomavirus (HPV)-related cancers has increased among people with HIV infection compared with the general population.
  • This review will describe recent findings in HPV-associated cancer incidence since the introduction of antiretroviral therapy, HPV/disease prevalence at sites other than cervix and anus, and recent data on screening and treatment of anal intraepithelial neoplasia.
  • RECENT FINDINGS: Consistent with high prevalence of anogenital HPV infection, new data on cervical intraepithelial neoplasia and anal intraepithelial neoplasia in HIV-positive men and women show that the incidence of cervical cancer has not declined since the introduction of antiretroviral therapy and that the incidence of anal cancer is rising.
  • Treatment methods for anal intraepithelial neoplasia have been described and show reasonable efficacy.
  • SUMMARY: New data imply that the problem of HPV-related cancers will not decline among HIV-positive men and women in the antiretroviral therapy era, highlighting the need to perform studies to determine if screening and treatment of anal intraepithelial neoplasia will prevent development of anal cancer.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] J Invest Dermatol. 2008 Sep;128(9):2316-24 [18385760.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):103-7 [18472205.001]
  • [Cites] J Oral Pathol Med. 2008 Oct;37(9):555-9 [18355174.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Int J STD AIDS. 2007 Aug;18(8):538-42 [17686215.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Int J STD AIDS. 2008 Jul;19(7):445-9 [18574114.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • (PMID = 19339939.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA054053-08; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA054053-08; United States / NCI NIH HHS / CA / R01 CA088739-03; United States / NCI NIH HHS / CA / CA088739-03
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS94538; NLM/ PMC2756707
  •  go-up   go-down


25. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP: Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol; 2009 Oct;72(1):10-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the impact of combined antiretroviral therapy (cART) on human immunodeficiency virus (HIV)-related mortality, malignancies remain the second most common cause of death in HIV infection in developed countries.
  • In addition to the AIDS-defining malignancies, other cancers such as Hodgkin's lymphoma and anal cancer, are more frequent in HIV-infected patients who survive longer even though they do not have complete immune restoration The use of concomitant antineoplastic chemotherapy and cART have been demonstrated to be feasible and effective in patients with HIV-related malignancies; however, many drugs used in cART regimens have the potential for causing drug interactions as a result of their ability to either inhibit or induce the cytochrome P450 (CYP) enzyme system.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070506.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 77
  •  go-up   go-down


26. Clifford GM, Franceschi S: Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol; 2009 Jun;5(5):669-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk in HIV-infected persons: influence of CD4(+) count.
  • Whereas Kaposi sarcoma and non-Hodgkin lymphoma were recognised as AIDS-defining illnesses early in the HIV epidemic, the influence of declining CD4(+) count on other infection-related cancers has taken longer to establish, undoubtedly because the association is weaker and the dose-response relationship is less steep.
  • However, following improved survival made possible by combined antiretroviral therapy, declining CD4(+) count starts showing an impact on the natural history of various carcinogenic infections and on the risk for an increasingly wide range of cancers, including Hodgkin lymphoma, cervical, anal and liver cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519206.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


27. Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, Jans DA, Harrich D: Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol; 2009 Nov;83(22):11694-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stabilizing action of PRMT6 could allow Tat to persist within the cell and the extracellular environment and thereby enable functions implicated in AIDS-related cancer, neurodegeneration, and T-cell death.

  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Jan 27;124(2):381-92 [16439211.001]
  • [Cites] Retrovirology. 2009;6:1 [19128510.001]
  • [Cites] Mol Cell. 2006 Apr 7;22(1):51-62 [16600869.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1347-57 [16697675.001]
  • [Cites] Retrovirology. 2006;3:48 [16893449.001]
  • [Cites] J Cell Biol. 2006 Nov 6;175(3):401-13 [17088425.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):120-34 [17043108.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):214-8 [17215844.001]
  • [Cites] Retrovirology. 2006;3:93 [17176473.001]
  • [Cites] Mol Cell. 2007 Feb 9;25(3):369-83 [17289585.001]
  • [Cites] J Virol. 2007 Apr;81(8):4226-34 [17267505.001]
  • [Cites] AIDS. 2007 Apr 23;21(7):795-805 [17415034.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):831-42 [17588518.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):843-52 [17588519.001]
  • [Cites] Curr HIV Res. 2007 Sep;5(5):473-83 [17896967.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):933-7 [17898714.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):6106-18 [10545121.001]
  • [Cites] Mol Ther. 2000 Oct;2(4):404-14 [11020357.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28179-84 [11384967.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(23):7956-70 [11689688.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3537-43 [11724789.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3516-25 [12093752.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):209-15 [12115727.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):754-61 [12883554.001]
  • [Cites] Gene. 2004 Feb 4;326:1-11 [14729258.001]
  • [Cites] Eur J Clin Invest. 2004 Jan;34(1):57-66 [14984439.001]
  • [Cites] Cell. 2004 Jun 11;117(6):690-1 [15186770.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):559-71 [15327772.001]
  • [Cites] J Mol Biol. 1971 Dec 28;62(3):465-77 [5136579.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Nature. 1990 May 3;345(6270):84-6 [2184372.001]
  • [Cites] Biotechniques. 1991 Dec;11(6):739-40, 742-3 [1809326.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10501-9 [7683681.001]
  • [Cites] Arch Virol. 1994;137(1-2):149-55 [7979988.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7844-50 [8631829.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):974-7 [8757599.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8145-8 [9079628.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1224-35 [9135139.001]
  • [Cites] Cell. 1998 Feb 20;92(4):451-62 [9491887.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):384-9 [9514931.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;61:65-131 [9752719.001]
  • [Cites] Virology. 1998 Dec 5;252(1):126-36 [9875323.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):353-60 [15525938.001]
  • [Cites] J Virol. 2005 Jan;79(1):124-31 [15596808.001]
  • [Cites] PLoS Biol. 2005 Feb;3(2):e41 [15719057.001]
  • [Cites] Endocr Rev. 2005 Apr;26(2):147-70 [15479858.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):263-72 [15866169.001]
  • [Cites] J Exp Med. 2005 Aug 1;202(3):371-7 [16061726.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6402-11 [16272292.001]
  • [Cites] Microbes Infect. 2005 Oct;7(13):1364-9 [16046164.001]
  • [Cites] Science. 2007 Oct 19;318(5849):444-7 [17947579.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3369-80 [18079182.001]
  • [Cites] Retrovirology. 2008;5:40 [18498648.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1433-9 [18418067.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1780(9):1062-9 [18573314.001]
  • [Cites] Retrovirology. 2008;5:63 [18620576.001]
  • [Cites] J Biol Chem. 2006 Feb 17;281(7):3764-72 [16293633.001]
  • (PMID = 19726520.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / tat Gene Products, Human Immunodeficiency Virus; 94ZLA3W45F / Arginine; EC 2.1.1.- / PRMT6 protein, human; EC 2.1.1.- / Protein-Arginine N-Methyltransferases
  • [Other-IDs] NLM/ PMC2772670
  •  go-up   go-down


28. Kim JJ: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis; 2010 Dec;10(12):845-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A vaccine targeting human papillomavirus (HPV) types 16 and 18, which are associated with 80% of anal cancers, is efficacious in men.
  • METHODS: I constructed decision-analytic models to estimate the direct health and economic outcomes of HPV vaccination (against types 6, 11, 16, and 18) for prevention of HPV-related anal cancer and genital warts.
  • I used the models to conduct sensitivity analyses, including duration of vaccine protection, vaccine cost, and burden of anal cancer and genital warts.
  • Outcomes were most sensitive to variations in anal cancer incidence, duration of vaccine protection, and HIV prevalence in MSM.
  • INTERPRETATION: HPV vaccination of MSM is likely to be a cost-effective intervention for the prevention of genital warts and anal cancer.
  • FUNDING: US National Cancer Institute.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Lancet. 2007 Jun 2;369(9576):1861-8 [17544766.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):293-304 [18559368.001]
  • [Cites] Med Decis Making. 2002 Sep-Oct;22(5):417-30 [12365484.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] Value Health. 2004 Sep-Oct;7(5):518-28 [15367247.001]
  • [Cites] Med Decis Making. 1993 Apr-Jun;13(2):89-102 [8483408.001]
  • [Cites] Med Care. 1998 Jun;36(6):778-92 [9630120.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Jun 24;54(24):597-601 [15973239.001]
  • [Cites] Med Decis Making. 2005 Nov-Dec;25(6):667-77 [16282217.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28 [17237032.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):57-63 [19339940.001]
  • [Cites] Sex Transm Dis. 2009 Aug;36(8):515-21 [19543143.001]
  • [Cites] Lancet. 2009 Jul 25;374(9686):301-14 [19586656.001]
  • [Cites] Curr Med Res Opin. 2009 Oct;25(10):2343-51 [19650749.001]
  • [Cites] BMJ. 2009;339:b3884 [19815582.001]
  • [Cites] Health Econ. 2010 Apr;19(4):422-37 [19382128.001]
  • [Cites] J Adolesc Health. 2010 Apr;46(4 Suppl):S12-9 [20307839.001]
  • [Cites] Sex Transm Dis. 2010 Jun;37(6):399-405 [20473245.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630-2 [20508594.001]
  • [Cites] BMJ. 2010;341:c3493 [20647284.001]
  • [Cites] Vaccine. 2010 Aug 31;28(38):6247-55 [20643092.001]
  • [Cites] Hum Vaccin. 2009 Oct;5(10):696-704 [19855170.001]
  • [Cites] Vaccine. 2010 Oct 4;28(42):6858-67 [20713101.001]
  • [Cites] Cancer. 2010 Dec 1;116(23):5507-16 [20672354.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Am J Obstet Gynecol. 2008 May;198(5):500.e1-7 [18455524.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] BMJ. 2008;337:a769 [18640957.001]
  • [CommentIn] Lancet Infect Dis. 2010 Dec;10(12):815-6 [21051294.001]
  • (PMID = 21051295.001).
  • [ISSN] 1474-4457
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093435; United States / NCI NIH HHS / CA / R01 CA93435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS561569; NLM/ PMC3982926
  •  go-up   go-down


29. Buonaguro L, Petrizzo A, Tornesello M, Napolitano M, Martorelli D, Castello G, Beneduce G, De Renzo A, Perrella O, Romagnoli L, Sousa V, De Re V, Dolcetti R, Buonaguro FM: Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med; 2010;8:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.
  • Hepatitis C virus (HCV) is one of the major risk factors for chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma, as well as for type II mixed cryoglobulinemia (MC), which may further evolve into an overt B-cell non-Hodgkin's lymphoma (NHL).

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):211-6 [10861476.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3578-84 [11071657.001]
  • [Cites] J Clin Lab Anal. 2002;16(1):40-6 [11835530.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):571-80 [12353944.001]
  • [Cites] Turk J Gastroenterol. 2003 Mar;14(1):7-11 [14593531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]
  • [Cites] Cell Res. 2004 Jun;14(3):251-6 [15225419.001]
  • [Cites] J Exp Med. 1989 Sep 1;170(3):827-45 [2504877.001]
  • [Cites] Ann Intern Med. 1992 Oct 1;117(7):573-7 [1326246.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):1041-8 [8102388.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3701-4 [8260706.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1109-18 [8145033.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):211-22 [7516408.001]
  • [Cites] J Intern Med. 1994 Jul;236(1):31-6 [8021570.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] J Hepatol. 1997 Mar;26(3):471-8 [9075651.001]
  • [Cites] Clin Rev Allergy Immunol. 1997 Spring;15(1):97-119 [9209804.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Mediators Inflamm. 1998;7(4):295-7 [9792341.001]
  • [Cites] Science. 1998 Oct 30;282(5390):938-41 [9794763.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1666-73 [10415073.001]
  • [Cites] J Hepatol. 2005 Jan;42(1):61-7 [15629508.001]
  • [Cites] J Virol. 2005 Mar;79(5):3052-62 [15709025.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 May;17(5):477-83 [15827436.001]
  • [Cites] J Infect Dis. 2005 Aug 1;192(3):497-503 [15995965.001]
  • [Cites] J Virol. 2006 Sep;80(18):9134-43 [16940524.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1205-7 [17383452.001]
  • [Cites] World J Gastroenterol. 2007 May 7;13(17):2467-78 [17552031.001]
  • [Cites] Clin Vaccine Immunol. 2007 Sep;14(9):1127-37 [17634507.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1344-56 [17942751.001]
  • [Cites] BMC Bioinformatics. 2008;9 Suppl 2:S5 [18387207.001]
  • [Cites] Autoimmun Rev. 2008 Jun;7(6):468-72 [18558364.001]
  • [Cites] Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S39-47 [18570753.001]
  • [Cites] J Virol. 2009 Jan;83(1):304-13 [18945779.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):116-25 [19029902.001]
  • [Cites] J Exp Med. 2008 Dec 22;205(13):3119-31 [19047440.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Aug;7(8):900-5 [19362606.001]
  • [Cites] AIDS Res Hum Retroviruses. 2009 Aug;25(8):819-22 [19630502.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):675-81 [19701243.001]
  • [Cites] FEBS Lett. 2009 Sep 17;583(18):3004-8 [19665024.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1173:152-60 [19758144.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):223-31 [7516409.001]
  • (PMID = 20170491.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines; 0 / Immunoglobulin Idiotypes; 0 / Immunoglobulin Variable Region; 0 / Receptors, Antigen, B-Cell; 0 / Viral Vaccines
  • [Other-IDs] NLM/ PMC2839974
  •  go-up   go-down


31. López-Huertas MR, Callejas S, Abia D, Mateos E, Dopazo A, Alcamí J, Coiras M: Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Res; 2010 Jun;38(10):3287-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second, cytoskeleton-related functions as cell morphology, proliferation, chemotaxis, polarization and actin polymerization were deeply altered in Jurkat-Tat101, but not in Jurkat-Tat72.
  • Consequently, these modifications were greatly dependent on Tat second exon and they could be related to the anergy observed in HIV-1-infected T cells.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2004;32(4):1270-8 [14981150.001]
  • [Cites] Eur J Clin Invest. 2004 Jan;34(1):57-66 [14984439.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):14331-7 [14718541.001]
  • [Cites] PLoS Biol. 2004 Jan;2(1):E6 [14737186.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Mar;20(3):297-304 [15117453.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5193-202 [15122328.001]
  • [Cites] Virology. 2004 Aug 15;326(1):79-89 [15262497.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Mol Biol. 1993 Mar 5;230(1):90-110 [8450553.001]
  • [Cites] J Virol. 1993 Jul;67(7):3739-47 [8510203.001]
  • [Cites] Virology. 1993 Aug;195(2):826-30 [8337847.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7941-5 [7690138.001]
  • [Cites] J Virol. 1993 Nov;67(11):6596-604 [8411362.001]
  • [Cites] J Biol Chem. 1993 Nov 25;268(33):24940-9 [8227056.001]
  • [Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]
  • [Cites] J Clin Invest. 1994 Jun;93(6):2505-13 [7515393.001]
  • [Cites] Nucleic Acids Res. 1994 Oct 25;22(21):4405-13 [7971271.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):546-54 [7859743.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2026-30 [7892219.001]
  • [Cites] Ann Neurol. 1995 Mar;37(3):373-80 [7695237.001]
  • [Cites] J Virol. 1999 Mar;73(3):1956-63 [9971775.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1581-8 [10102628.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3645-53 [10207088.001]
  • [Cites] J Virol. 1999 Aug;73(8):7080-6 [10400814.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):28837-40 [10506122.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48197-204 [15331610.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:932-41 [15818415.001]
  • [Cites] Retrovirology. 2005;2:5 [15691386.001]
  • [Cites] Retrovirology. 2005;2:6 [15698475.001]
  • [Cites] New Microbiol. 2005 Apr;28(2):95-109 [16035254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16362-7 [16260749.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38376-82 [16155003.001]
  • [Cites] J Neurosci. 2006 Apr 12;26(15):4054-62 [16611822.001]
  • [Cites] Proteomics. 2006 Apr;6 Suppl 1:S63-73 [16526095.001]
  • [Cites] J Gen Virol. 2006 Jun;87(Pt 6):1603-12 [16690925.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10439-48 [17079465.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34574-91 [16935861.001]
  • [Cites] Cell. 1986 Sep 26;46(7):1053-61 [3463433.001]
  • [Cites] J Cell Biol. 1977 Nov;75(2 Pt 1):593-605 [233748.001]
  • [Cites] EMBO J. 1988 Oct;7(10):3143-7 [3181132.001]
  • [Cites] J Virol. 1989 Mar;63(3):1181-7 [2536828.001]
  • [Cites] J Virol. 1989 Dec;63(12):5501-4 [2479775.001]
  • [Cites] Science. 1989 Dec 22;246(4937):1606-8 [2556795.001]
  • [Cites] J Virol. 1991 Feb;65(2):961-7 [1898974.001]
  • [Cites] Proteins. 1991;9(3):180-90 [2006136.001]
  • [Cites] Nature. 1991 Apr 25;350(6320):709-12 [2023633.001]
  • [Cites] J Virol. 1991 Jul;65(7):3460-7 [1645777.001]
  • [Cites] J Virol. 1992 Jun;66(6):3883-7 [1583734.001]
  • [Cites] J Exp Med. 1992 Sep 1;176(3):739-50 [1512539.001]
  • [Cites] Eur J Immunol. 1992 Oct;22(10):2729-32 [1396975.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 25;20(20):5465-72 [1437564.001]
  • [Cites] J Virol. 1993 Jan;67(1):277-87 [8416373.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2917-23 [8428966.001]
  • [Cites] J Immunol. 1993 Mar 15;150(6):2544-53 [8095514.001]
  • [Cites] Science. 1995 Apr 21;268(5209):429-31 [7716549.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1552-60 [7729429.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):497-500 [7539892.001]
  • [Cites] Exp Cell Res. 1995 Jul;219(1):180-96 [7628534.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;193:51-77 [7648878.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Sep;11(9):1039-48 [8554901.001]
  • [Cites] Annu Rev Immunol. 1996;14:591-617 [8717526.001]
  • [Cites] Med Hypotheses. 1995 Nov;45(5):486-90 [8748093.001]
  • [Cites] J Virol. 1996 Nov;70(11):7734-43 [8892894.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):1014-9 [8993024.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):551-60 [9031086.001]
  • [Cites] J Virol. 1997 Mar;71(3):2495-9 [9032389.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2107-15 [9036955.001]
  • [Cites] Science. 1997 Mar 7;275(5305):1481-5 [9045614.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1224-35 [9135139.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13803-9 [9153236.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):16010-7 [9188504.001]
  • [Cites] J Cell Biol. 1997 Sep 22;138(6):1409-23 [9298994.001]
  • [Cites] Eur J Immunol. 1997 Nov;27(11):2805-11 [9394803.001]
  • [Cites] J Exp Med. 1998 Mar 16;187(6):875-83 [9500790.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):384-9 [9514931.001]
  • [Cites] J Virol. 1998 Jul;72(7):6113-8 [9621075.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jun;57(6):563-70 [9630236.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13153-8 [9789057.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1553-9 [9840288.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] J Leukoc Biol. 2008 Mar;83(3):718-27 [18070983.001]
  • [Cites] EMBO J. 2008 Jul 9;27(13):1907-18 [18566585.001]
  • [Cites] Retrovirology. 2008;5:62 [18613978.001]
  • [Cites] Mol Biol Cell. 2008 Nov;19(11):4660-74 [18716063.001]
  • [Cites] Development. 2008 Dec;135(23):3871-9 [18948417.001]
  • [Cites] J Virol. 2008 Dec;82(23):11958-63 [18922876.001]
  • [Cites] Nat Struct Mol Biol. 2008 Dec;15(12):1287-92 [19029897.001]
  • [Cites] Retrovirology. 2009;6:47 [19454010.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Oct 15;240(2):286-91 [19576918.001]
  • [Cites] J Virol. 2000 Jan;74(1):344-53 [10590123.001]
  • [Cites] Trends Pharmacol Sci. 2000 Feb;21(2):45-8 [10664605.001]
  • [Cites] Histol Histopathol. 2000 Apr;15(2):539-49 [10809375.001]
  • [Cites] J Neurochem. 2000 Jul;75(1):109-16 [10854253.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5077-86 [10866664.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):151-8 [10899902.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11466-71 [11027346.001]
  • [Cites] C R Acad Sci III. 2000 Oct;323(10):883-94 [11098404.001]
  • [Cites] Eur J Immunol. 2001 Apr;31(4):969-79 [11298321.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5402-6 [11454683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41 [11517324.001]
  • [Cites] IUBMB Life. 2001 Mar;51(3):175-81 [11547919.001]
  • [Cites] Cell. 2001 Oct 5;107(1):27-41 [11595183.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 15):2787-94 [11683412.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10400-9 [11784723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10037-41 [12096189.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30551-8 [12055194.001]
  • [Cites] Protein Sci. 2002 Nov;11(11):2606-21 [12381844.001]
  • [Cites] J Cell Biol. 2002 Nov 11;159(3):441-52 [12417576.001]
  • [Cites] BMC Biochem. 2002 Jun 10;3:14 [12069692.001]
  • [Cites] EMBO J. 2002 Dec 16;21(24):6801-10 [12486001.001]
  • [Cites] Nat Med. 2003 Feb;9(2):191-7 [12539042.001]
  • [Cites] Virology. 2003 Mar 1;307(1):154-63 [12667823.001]
  • [Cites] J Leukoc Biol. 2003 May;73(5):556-63 [12714569.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):525-32 [12717432.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44816-25 [12947089.001]
  • [Cites] J Virol. 2004 Jan;78(2):779-89 [14694110.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4541-50 [14623895.001]
  • (PMID = 20139419.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / tat Gene Products, Human Immunodeficiency Virus; 0 / tat peptide (1-72), Human immunodeficiency virus 1
  • [Other-IDs] NLM/ PMC2879518
  •  go-up   go-down


32. Kreuter A, Hochdorfer B, Brockmeyer NH, Altmeyer P, Pfister H, Wieland U, Competence Network HIV/AIDS: A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome. Arch Dermatol; 2008 Mar;144(3):366-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although skin cancer frequently develops in the sun-exposed cutaneous lesions of patients with EV, the anogenital area is usually not affected by squamous cell carcinomas related to mucosal HPV types.
  • [MeSH-minor] Adult. Anal Canal / pathology. Diagnosis, Differential. Female. Genitalia, Female / pathology. Humans. Papillomaviridae / classification. Papillomaviridae / isolation & purification. Syndrome

  • Genetic Alliance. consumer health - Lymphedema.
  • MedlinePlus Health Information. consumer health - Lymphedema.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347293.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Dhir AA, Sawant SP: Malignancies in HIV: the Indian scenario. Curr Opin Oncol; 2008 Sep;20(5):517-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: India has the second largest number of HIV/AIDS patients in the world; however, studies done in the area of HIV-related malignancies are few.
  • With the availability of highly active antiretroviral therapy and treatment and prevention of opportunistic infections, an increase in life expectancy of HIV-infected individuals and an increase in HIV-related malignancies is expected.
  • The purpose of this review is to put forth the Indian scenario of HIV-related malignancies.
  • RECENT FINDINGS: About 2.5 million Indians have HIV/AIDS.
  • Non-Hodgkin's lymphoma and cervical cancer were found to occur in a higher proportion among the HIV-infected individuals in India as compared with non-HIV-infected individuals.
  • The incidence of AIDS-related primary central nervous system lymphoma is low in India.
  • Amongst the non-AIDS defining cancers anal cancer, testicular cancer, Hodgkin's disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.
  • As India is a large country and geographically and culturally diverse, large-scale studies need to be done linking the regional cancer centres with the AIDS centres across the country to evaluate the exact burden of HIV-related malignancies.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / etiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106653.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


34. Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS: Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis; 2010 Mar;37(3):197-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Due to higher rates of human papillomavirus (HPV) infection and anal cancer among gay and bisexual men, we aimed to characterize their willingness to get HPV vaccine and identify correlates of vaccine acceptability.
  • Acceptability was also higher among men who reported 5 or more lifetime sexual partners (OR = 3.39, 95% CI: 1.34-8.55), perceived greater severity of HPV-related disease (OR = 1.92, 95% CI: 1.18-3.14), perceived higher levels of HPV vaccine effectiveness (OR = 1.97, 95% CI: 1.27-3.06), or reported higher levels of anticipated regret if they did not get vaccinated and later developed an HPV infection (OR = 2.39, 95% CI: 1.57-3.61).

  • MedlinePlus Health Information. consumer health - Gay, Lesbian, Bisexual, and Transgender Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2008 Jun 15;197(12):1676-84 [18426367.001]
  • [Cites] J Womens Health (Larchmt). 2008 May;17(4):539-48 [18370586.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43 [18708396.001]
  • [Cites] J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7 [18809147.001]
  • [Cites] J Low Genit Tract Dis. 2008 Oct;12(4):276-81 [18820541.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K68-75 [18847559.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):3036-46 [18980286.001]
  • [Cites] Public Health. 2008 Dec;122(12):1295-301 [18619631.001]
  • [Cites] Sex Transm Dis. 2009 Jan;36(1):58-62 [18830138.001]
  • [Cites] J Am Board Fam Med. 2009 Jan-Feb;22(1):34-42 [19124631.001]
  • [Cites] Vaccine. 2008 Dec 2;26(51):6529-41 [18805453.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Soc Sci Med. 2009 Aug;69(3):475-80 [19540642.001]
  • [Cites] Am J Mens Health. 2011 Jul;5(4):297-305 [20798149.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Arch Sex Behav. 2004 Dec;33(6):585-91 [15483372.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] J Clin Microbiol. 1995 Aug;33(8):2058-63 [7559948.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):437-43 [16159738.001]
  • [Cites] Int J STD AIDS. 2005 Oct;16(10):707-8 [16212721.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Sex Transm Dis. 2007 Mar;34(3):170-3 [16837830.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • [Cites] Prev Med. 2007 Aug-Sep;45(2-3):107-14 [17628649.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1137-45 [17955431.001]
  • [Cites] J Infect Dis. 2007 Nov 15;196(10):1431-2 [18008218.001]
  • [Cites] J Adolesc Health. 2008 Mar;42(3):237-42 [18295131.001]
  • [Cites] J Am Coll Health. 2008 Jul-Aug;57(1):23-32 [18682342.001]
  • (PMID = 20118831.001).
  • [ISSN] 1537-4521
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA057726; United States / NCI NIH HHS / CA / R25 CA57726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS578642; NLM/ PMC4018212
  •  go-up   go-down


35. Casares S, Ab E, Eshuis H, Lopez-Mayorga O, van Nuland NA, Conejero-Lara F: The high-resolution NMR structure of the R21A Spc-SH3:P41 complex: understanding the determinants of binding affinity by comparison with Abl-SH3. BMC Struct Biol; 2007;7:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interactions with SH3 domains play a crucial role in regulation of many cellular processes (some are related to cancer and AIDS) and have thus been interesting targets in drug design.

  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Hazardous Substances Data Bank. Water .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21 [9757107.001]
  • [Cites] Protein Sci. 2005 Jan;14(1):81-8 [15576569.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2088-92 [9851931.001]
  • [Cites] Biochemistry. 1999 Jul 13;38(28):8899-906 [10413463.001]
  • [Cites] Chem Biol Drug Des. 2006 Jan;67(1):38-45 [16492147.001]
  • [Cites] J Phys Chem B. 2005 Jan 13;109(1):662-70 [16851059.001]
  • [Cites] Proteins. 2007 May 15;67(3):531-47 [17330285.001]
  • [Cites] FASEB J. 2000 Feb;14(2):231-41 [10657980.001]
  • [Cites] Chem Biol. 2000 Jan;7(1):R3-8 [10662684.001]
  • [Cites] Protein Sci. 2000 Oct;9(10):1975-85 [11106171.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 7):1253-63 [11256992.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17199-205 [11278857.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Nov;40(2):175-86 [11682324.001]
  • [Cites] J Mol Biol. 2001 Nov 2;313(4):873-87 [11697910.001]
  • [Cites] Cell Biochem Biophys. 2001;35(2):127-40 [11892788.001]
  • [Cites] FEBS Lett. 2002 Mar 13;514(2-3):295-9 [11943169.001]
  • [Cites] J Mol Biol. 2002 May 24;319(1):209-27 [12051947.001]
  • [Cites] Proteins. 2002 Nov 1;49(2):181-90 [12210999.001]
  • [Cites] Biopolymers. 1997;43(5):383-400 [9566119.001]
  • [Cites] J Mol Biol. 1998 Aug 21;281(3):513-21 [9698566.001]
  • [Cites] Methods Enzymol. 1998;295:294-315 [9750224.001]
  • [Cites] FEBS Lett. 2002 Sep 11;527(1-3):86-90 [12220639.001]
  • [Cites] Adv Protein Chem. 2002;61:211-68 [12461825.001]
  • [Cites] Proteins. 2003 Feb 15;50(3):496-506 [12557191.001]
  • [Cites] J Am Chem Soc. 2003 Feb 19;125(7):1731-7 [12580598.001]
  • [Cites] Protein Sci. 2003 Mar;12(3):447-57 [12592015.001]
  • [Cites] FEBS Lett. 2003 Mar 27;539(1-3):125-30 [12650939.001]
  • [Cites] J Mol Biol. 2004 Feb 13;336(2):527-37 [14757063.001]
  • [Cites] J Mol Biol. 2004 Feb 27;336(4):829-42 [15095863.001]
  • [Cites] Biochemistry. 2004 Jun 22;43(24):7787-97 [15196021.001]
  • [Cites] J Mol Biol. 1971 Feb 14;55(3):379-400 [5551392.001]
  • [Cites] Nucleic Acids Res. 1988 Aug 11;16(15):7351-67 [3045756.001]
  • [Cites] Anal Biochem. 1989 Nov 1;182(2):319-26 [2610349.001]
  • [Cites] Proteins. 1992 Apr;12(4):345-64 [1579569.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):851-5 [1279434.001]
  • [Cites] Proteins. 1993 Sep;17(1):75-86 [8234246.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1089-93 [8302837.001]
  • [Cites] Science. 1994 Feb 11;263(5148):777-84 [8303294.001]
  • [Cites] Biochemistry. 1994 Sep 13;33(36):10925-33 [8086409.001]
  • [Cites] Biochemistry. 1995 Apr 18;34(15):5224-33 [7711042.001]
  • [Cites] Protein Eng. 1995 Feb;8(2):127-34 [7630882.001]
  • [Cites] J Biomol NMR. 1995 Nov;6(3):277-93 [8520220.001]
  • [Cites] Biochemistry. 1996 Aug 20;35(33):10634-40 [8718852.001]
  • [Cites] Biochemistry. 1996 Dec 10;35(49):15646-53 [8961927.001]
  • [Cites] J Biomol NMR. 1997 Jun;9(4):347-57 [9255941.001]
  • [Cites] J Mol Biol. 1997 Oct 17;273(1):283-98 [9367762.001]
  • [Cites] Biochemistry. 1998 Oct 20;37(42):14683-91 [9778343.001]
  • (PMID = 17407569.001).
  • [ISSN] 1472-6807
  • [Journal-full-title] BMC structural biology
  • [ISO-abbreviation] BMC Struct. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / Peptides; 059QF0KO0R / Water; 12634-43-4 / Spectrin; 94ZLA3W45F / Arginine; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl; OF5P57N2ZX / Alanine
  • [Other-IDs] NLM/ PMC1853097
  •  go-up   go-down


36. Denny P, Hagen FK, Hardt M, Liao L, Yan W, Arellanno M, Bassilian S, Bedi GS, Boontheung P, Cociorva D, Delahunty CM, Denny T, Dunsmore J, Faull KF, Gilligan J, Gonzalez-Begne M, Halgand F, Hall SC, Han X, Henson B, Hewel J, Hu S, Jeffrey S, Jiang J, Loo JA, Ogorzalek Loo RR, Malamud D, Melvin JE, Miroshnychenko O, Navazesh M, Niles R, Park SK, Prakobphol A, Ramachandran P, Richert M, Robinson S, Sondej M, Souda P, Sullivan MA, Takashima J, Than S, Wang J, Whitelegge JP, Witkowska HE, Wolinsky L, Xie Y, Xu T, Yu W, Ytterberg J, Wong DT, Yates JR 3rd, Fisher SJ: The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. J Proteome Res; 2008 May;7(5):1994-2006
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultimately, information derived from the work reported here and related published studies can be used to translate blood-based clinical laboratory tests into a format that utilizes saliva.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2004 Sep-Oct;3(5):1017-23 [15473691.001]
  • [Cites] Arch Oral Biol. 2004 Dec;49(12):951-62 [15485636.001]
  • [Cites] Int J Oncol. 2004 Nov;25(5):1423-30 [15492834.001]
  • [Cites] J Dent Res. 1987 Feb;66 Spec No:623-7 [3497964.001]
  • [Cites] Obstet Gynecol. 1990 Apr;75(4):701-4 [2179784.001]
  • [Cites] Biol Chem Hoppe Seyler. 1991 May;372(5):325-9 [1714742.001]
  • [Cites] J Biol Chem. 1991 Sep 15;266(26):17358-68 [1894623.001]
  • [Cites] J Biol Chem. 1991 Sep 25;266(27):17972-7 [1655733.001]
  • [Cites] Mol Immunol. 1993 Feb;30(3):277-86 [8433706.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(3-4):251-9 [8373982.001]
  • [Cites] Ann N Y Acad Sci. 1993 Sep 20;694:11-6 [8215048.001]
  • [Cites] Crit Rev Oral Biol Med. 1995;6(2):161-75 [7548622.001]
  • [Cites] Acta Paediatr. 1996 Jul;85(7):814-7 [8819547.001]
  • [Cites] Clin Chem. 1999 Sep;45(9):1431-8 [10471645.001]
  • [Cites] J Neurosci Res. 1999 Oct 15;58(2):301-7 [10502286.001]
  • [Cites] Biochemistry. 2005 Feb 15;44(6):2216-24 [15697247.001]
  • [Cites] Proteomics. 2006 Dec;6(23):6326-53 [17083142.001]
  • [Cites] Laryngorhinootologie. 2006 Dec;85(12):903-8 [16612747.001]
  • [Cites] Genome Biol. 2006;7(9):R80 [16948836.001]
  • [Cites] Genome Biol. 2006;7(8):R72 [16901338.001]
  • [Cites] J Neurochem. 2007 Nov;103(3):849-59 [17666040.001]
  • [Cites] Arthritis Rheum. 2007 Nov;56(11):3588-600 [17968930.001]
  • [Cites] Proteomics. 2008 Feb;8(3):435-45 [18186022.001]
  • [Cites] Am J Med Sci. 1999 Dec;318(6):380-91 [10616163.001]
  • [Cites] Oral Oncol. 2000 May;36(3):272-6 [10793330.001]
  • [Cites] J Dent Res. 2000 Apr;79(4):976-82 [10831101.001]
  • [Cites] J Pathol. 2000 Sep;192(1):52-7 [10951400.001]
  • [Cites] J Clin Periodontol. 2000 Nov;27(11):810-8 [11073323.001]
  • [Cites] Oral Microbiol Immunol. 2000 Feb;15(1):10-4 [11155158.001]
  • [Cites] Nat Biotechnol. 2001 Mar;19(3):242-7 [11231557.001]
  • [Cites] J Prosthet Dent. 2001 Feb;85(2):162-9 [11208206.001]
  • [Cites] Anat Rec. 2001 Oct 1;264(2):121-45 [11590591.001]
  • [Cites] Nature. 2002 Jan 10;415(6868):141-7 [11805826.001]
  • [Cites] Bioinformatics. 2002 Jan;18(1):207-8 [11836235.001]
  • [Cites] Adv Dent Res. 2000 Dec;14:22-8 [11842920.001]
  • [Cites] J Can Dent Assoc. 2002 Mar;68(3):170-4 [11911813.001]
  • [Cites] Gerontology. 2002 Sep-Oct;48(5):282-8 [12169792.001]
  • [Cites] Arch Oral Biol. 2002 Sep;47(9):631-5 [12243966.001]
  • [Cites] Mol Biotechnol. 2002 Sep;22(1):51-86 [12353914.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5300-8 [12444093.001]
  • [Cites] J Proteome Res. 2002 Jan-Feb;1(1):21-6 [12643522.001]
  • [Cites] J Proteome Res. 2003 Jan-Feb;2(1):43-50 [12643542.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Sep;14(9):957-70 [12954164.001]
  • [Cites] J Periodontal Res. 2003 Dec;38(6):583-90 [14632921.001]
  • [Cites] Proteomics. 2004 Apr;4(4):1109-15 [15048992.001]
  • [Cites] Anal Chem. 2004 Jun 1;76(11):197A-203A [15190879.001]
  • [Cites] Mol Cell Proteomics. 2004 Jun;3(6):531-3 [15075378.001]
  • [Cites] Proteomics. 2004 Jul;4(7):1985-8 [15221759.001]
  • [Cites] Bioinformatics. 2004 Aug 4;20 Suppl 1:i49-54 [15262780.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1384-8 [15371956.001]
  • [Cites] Clin Physiol. 1996 Jul;16(4):433-48 [8842578.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Dec 4;229(1):193-7 [8954105.001]
  • [Cites] Anal Chem. 1997 Feb 15;69(4):767-76 [9043199.001]
  • [Cites] J Clin Periodontol. 1997 Jan;24(1):72-7 [9049801.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jan;42(1):83-6 [9116322.001]
  • [Cites] J Dent Res. 1997 Nov;76(11):1782-6 [9372796.001]
  • [Cites] Oral Dis. 1997 May;3 Suppl 1:S64-9 [9456660.001]
  • [Cites] Dig Dis Sci. 1998 Jun;43(6):1211-8 [9635610.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5922-8 [9637505.001]
  • [Cites] Fertil Steril. 1999 May;71(5):863-8 [10231047.001]
  • [Cites] Biochemistry. 2005 Mar 1;44(8):2885-99 [15723531.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Jan;5(1):93-100 [15723595.001]
  • [Cites] J Dent. 2005 Mar;33(3):223-33 [15725522.001]
  • [Cites] Nat Methods. 2004 Dec;1(3):195-202 [15789030.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1714-28 [15800970.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):159-67 [15890249.001]
  • [Cites] Expert Rev Proteomics. 2005 Aug;2(4):521-39 [16097886.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3226-45 [16104056.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3246-61 [16104057.001]
  • [Cites] Nat Methods. 2005 Sep;2(9):667-75 [16118637.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Sep;6(9):702-14 [16231421.001]
  • [Cites] Mol Cell Proteomics. 2005 Nov;4(11):1826-30 [16103422.001]
  • [Cites] Anal Chem. 2006 Jan 15;78(2):493-500 [16408932.001]
  • [Cites] J Physiol Biochem. 2005 Sep;61(3):469-80 [16440601.001]
  • [Cites] Int J Prosthodont. 2006 Jan-Feb;19(1):43-52 [16479760.001]
  • [Cites] Int J Prosthodont. 2006 Jan-Feb;19(1):53-60 [16479761.001]
  • [Cites] Proteomics. 2006 Mar;6(5):1631-9 [16402355.001]
  • [Cites] Nat Biotechnol. 2006 Mar;24(3):333-8 [16525410.001]
  • [Cites] J Am Dent Assoc. 2006 Mar;137(3):313-21 [16570464.001]
  • [Cites] Cell. 2006 Apr 7;125(1):173-86 [16615898.001]
  • [Cites] Eur J Oral Sci. 2006 Apr;114(2):147-53 [16630307.001]
  • [Cites] J Anat. 2006 May;208(5):609-19 [16637884.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):935-48 [16439352.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):787-8 [16670253.001]
  • [Cites] Pediatr Dent. 2006 Mar-Apr;28(2):110-7; discussion 192-8 [16708785.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1469-78 [16739998.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] J Chem Ecol. 2006 Jun;32(6):1149-63 [16770710.001]
  • [Cites] Am J Hum Biol. 2006 Jul-Aug;18(4):540-55 [16788889.001]
  • [Cites] J Neurochem. 2006 Jul;98(2):364-71 [16805831.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Aug;11(5):E449-55 [16878065.001]
  • [Cites] BMC Cancer. 2006;6:211 [16916471.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1811-8 [16735302.001]
  • [Cites] Curr HIV/AIDS Rep. 2006 Nov;3(4):169-75 [17032576.001]
  • [Cites] Neuroscience. 2006 Dec13;143(3):689-701 [16997486.001]
  • [Cites] J Dent Res. 2006 Dec;85(12):1129-33 [17122167.001]
  • (PMID = 18361515.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / U01 DE016267; United States / NIDCR NIH HHS / DE / U01 DE016275-04; United States / NIDCR NIH HHS / DE / DE016275-04; United States / NIDCR NIH HHS / DE / U01 DE016275; United States / NIDCR NIH HHS / DE / U01 DE016267-04; United States / NIDCR NIH HHS / DE / U01 DE 016274; United States / NIDCR NIH HHS / DE / U01 DE016274; United States / NIDCR NIH HHS / DE / DE016274-04; United States / NIDCR NIH HHS / DE / U01 DE016274-04; United States / NIDCR NIH HHS / DE / DE016267-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Proteome; 0 / Salivary Proteins and Peptides
  • [Other-IDs] NLM/ NIHMS109830; NLM/ PMC2839126
  •  go-up   go-down


37. Stier EA, Baranoski AS: Human papillomavirus-related diseases in HIV-infected individuals. Curr Opin Oncol; 2008 Sep;20(5):541-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related diseases in HIV-infected individuals.
  • RECENT FINDINGS: Studies assessing geographic variations in human papillomavirus types and prevalence in cervical dysplasia and cancer in HIV-infected women suggest that although human papillomavirus types 16 and 18 dominate, multiple other human papillomavirus types may play a role in carcinogenesis.
  • Anal dysplasia and cancer incidence continues to rise in the highly active antiretroviral therapy era; however, data on outcomes following therapy for anal dysplasia (infrared coagulator, high-resolution anoscopy-guided ablation) and anal cancer (chemoradiation and possibly intensity-modulated radiation therapy) have been encouraging.
  • Oral human papillomavirus may be associated with lower genital tract human papillomavirus infection and may have implications in the development of oropharyngeal cancer.
  • SUMMARY: As HIV-infected patients in the highly active antiretroviral therapy era continue to have high rates of cervical and anal cancer, it is important to continue screening efforts and treatment of preinvasive disease.
  • Treatment options for anal dysplasia and anal cancer in HIV-infected individuals are expanding and may lead to decreased morbidity and mortality.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):355-62 [16832413.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):684-90 [16855377.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2337-44 [17117020.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] J Clin Microbiol. 2006 Dec;44(12):4479-85 [17021055.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):61-5 [17075388.001]
  • [Cites] JAMA. 2007 Feb 28;297(8):813-9 [17327523.001]
  • [Cites] Int J STD AIDS. 2007 Feb;18(2):77-80 [17331275.001]
  • [Cites] J Low Genit Tract Dis. 2007 Apr;11(2):90-7 [17415113.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):CD005643 [17443606.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 May 1;45(1):9-19 [17356467.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1480-3 [17437020.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1908-10 [17494923.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Med Virol. 2007 Jun;79(6):758-65 [17457908.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1626-32 [17684137.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] J Infect Dis. 2007 Sep 15;196(6):887-94 [17703420.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60 [17714124.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1933-41 [17721101.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Am J Obstet Gynecol. 2007 Oct;197(4):346-55 [17904957.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2484-91 [17683070.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1589-97 [17942872.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):244-6 [17764116.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):84-8 [17483251.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/63-70 [16950019.001]
  • [Cites] Exp Mol Pathol. 2006 Aug;81(1):42-7 [16878360.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • (PMID = 19106657.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / U01 CA121947-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  • [Other-IDs] NLM/ NIHMS126311; NLM/ PMC2757652
  •  go-up   go-down


38. Pineda CE, Welton ML: Management of anal squamous intraepithelial lesions. Clin Colon Rectal Surg; 2009 May;22(2):94-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal squamous intraepithelial lesions.
  • Anal squamous intraepithelial lesions include both low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL) and are caused by chronic infection with the human papillomavirus (HPV).
  • The disease is increasing in both incidence and prevalence, especially among patients with the following risk factors: homosexual men, acquired or iatrogenic immunosuppression, and presence of other HPV-related diseases.
  • Although the natural history of the disease is unknown, there is significant evidence that untreated HSIL progresses to squamous cell carcinoma in 11% of patients and in up to 50% of patients with extensive disease and immunosuppression.
  • Anal cytology and reflex HPV DNA testing are used to screen for disease, particularly among patients with the aforementioned risk factors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):782-5 [3652891.001]
  • [Cites] Genitourin Med. 1994 Feb;70(1):22-5 [8300094.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Minerva Chir. 2008 Oct;63(5):389-99 [18923350.001]
  • [Cites] Am J Epidemiol. 1996 Nov 15;144(10):916-23 [8916502.001]
  • [Cites] Dis Colon Rectum. 1977 Oct;20(7):570-2 [913212.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] Am J Surg. 1979 Feb;137(2):231-4 [371426.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Am J Surg. 1954 Nov;88(5):710-4 [13197672.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1332-6; discussion 1336-8 [14530670.001]
  • [Cites] Arch Surg. 2004 Mar;139(3):259-61 [15006881.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1490-2 [15156490.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Int J Colorectal Dis. 2006 Mar;21(2):135-42 [15864603.001]
  • [Cites] J Low Genit Tract Dis. 2004 Oct;8(4):272-5 [15874871.001]
  • [Cites] J Surg Res. 2005 Jul 1;127(1):8-13 [15964301.001]
  • [Cites] Diagn Cytopathol. 2005 Sep;33(3):152-6 [16078257.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):126 [16222485.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] AIDS. 2006 May 12;20(8):1151-5 [16691066.001]
  • [Cites] Int J STD AIDS. 2007 Feb;18(2):77-80 [17331275.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Rev Assoc Med Bras. 2007 Mar-Apr;53(2):147-51 [17568919.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):453-60 [17586030.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1410-5; discussion 1415-6 [17710507.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60 [17714124.001]
  • [Cites] J Low Genit Tract Dis. 2007 Oct;11(4):201-22 [17917566.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):2-9 [18030528.001]
  • [Cites] Acta Cytol. 2007 Nov-Dec;51(6):893-9 [18077982.001]
  • [Cites] Am Surg. 2007 Dec;73(12):1279-83 [18186390.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1130-6 [18481150.001]
  • [Cites] Int J STD AIDS. 2008 Jul;19(7):445-9 [18574114.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Adv Anat Pathol. 2008 Sep;15(5):263-78 [18724100.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1063-6 [10460644.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):346-52 [10733116.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1992-8 [14655809.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1561-9 [15238774.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1470-5 [18299937.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1447-56 [15726546.001]
  • [Cites] Sex Transm Infect. 2005 Apr;81(2):142-6 [15800092.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5273-80 [16033846.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Dis Colon Rectum. 2007 Jul;50(7):1011-6 [17429713.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):32-9 [18667921.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]
  • (PMID = 20436833.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780238
  • [Keywords] NOTNLM ; Anal squamous dysplasia / high-grade squamous intraepithelial lesions / high-resolution anoscopy
  •  go-up   go-down


39. Tirado-Ramos A, Saltz J, Lechowicz MJ: HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes. Stud Health Technol Inform; 2010;159:239-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes.
  • Technological innovations such as web services and collaborative Grid platforms like caGrid can create opportunities to converge the worlds of health care and clinical research, by facilitating access and integration of HIV-related malignancy clinical and outcomes data at more sophisticated, semantic levels.
  • At the same time, large numbers of randomized clinical trial and outcomes data on AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) have been produced during the last few years.
  • This is a white paper on work in progress from Emory University's HIV/AIDS related malignancy data integrative knowledge base project (HIV-K).
  • We are working to increase the understanding of available clinical trial data and outcomes of ADM such as lymphoma, as well as nADM such as anal cancer, Hodgkin lymphoma, or liver cancer.
  • Our hypothesis is that, by creating prototypes of tools for semantics-enabled integrative knowledge bases for HIV/AIDS-related malignancy data, we will facilitate the identification of patterns and potential new overall evidence, as well as the linking of integrated data and results to registries of interest.
  • [MeSH-major] Databases, Factual. HIV-1. Lymphoma, AIDS-Related / therapy. Semantics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - How to Tell Patients .
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Dec 1;112(12):4384-99 [19029456.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] J Clin Exp Neuropsychol. 2010 Apr;32(4):398-407 [19763997.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Stat Med. 1988 Nov;7(11):1121-37 [3201038.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Public Health. 2005;95 Suppl 1:S144-50 [16030331.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1910-6 [16766552.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):335-42 [16782210.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • (PMID = 20543443.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409-11; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NCRR NIH HHS / RR / UL1 RR025008-04; United States / NCATS NIH HHS / TR / UL1 TR000454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS315000; NLM/ PMC3157699
  •  go-up   go-down


40. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities, such as malignancies, have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


41. Insinga RP, Dasbach EJ, Elbasha EH: Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics; 2005;23(11):1107-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
  • Comprehensive estimates of the annual economic burden associated with the prevention and treatment of anogenital HPV-related disease in the US population are currently unavailable.
  • The purpose of this paper is to (i) outline an analytic framework from which to estimate the annual economic burden of preventing and treating anogenital HPV-related disease in the US;.
  • Among eight US studies identified that describe the annual economic burden pertaining to one or more aspects of anogenital HPV-related disease, three met the review eligibility criteria (published between 1990 and 2004, examined multiple facets of annual anogenital HPV-related economic burden, and clearly articulated the data and methods used in the estimation process).
  • Estimates of the annual direct medical costs associated with cervical cancer were comparable across studies (range 300-400 million US dollars).
  • Only one study reported direct medical costs for anogenital warts (200 million US dollars) and routine cervical cancer screening (2.3 billion US dollars).
  • No studies examined direct medical costs attributable to HPV-related anal, penile, vaginal or vulvar cancers, or the work and productivity losses resulting from time spent receiving medical care, morbidity or mortality.
  • Current economic burden estimates would suggest annual direct medical costs associated with the prevention and treatment of anogenital warts and cervical HPV-related disease of at least 4 billion US dollars.